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The use of plants as medicine for human health has been documented on 5000-
year-old Sumerian clay slabs, which also serve as the first evidence of written language. 
From 1940 to 2014, 83 % of small molecule anti-cancer treatments and 67 % of small-
molecule anti-infective drugs were discovered from or modeled after compounds found 
in nature. Furthermore, botanical medicines constitute a large portion of dietary 
supplements, with sales in the United States exceeding $7 billion in 2016. Natural 
product mixtures are chemically complex with multifaceted bioactivity, which further 
complicates the goal of understanding how these mixtures interact with specific 
biological systems. High resolving-power mass spectrometry coupled to ultra-high 
pressure liquid chromatography has played a significant role in making natural product 
research more efficient and reliable by improving the quality of biological measurements 
and by assisting in guiding isolation. The goals of this project were to: (1) develop a mass 
spectrometry-based assay that could be used to discover compounds that inhibit the 
spread of Staphylococcus aureus in the skin and to (2) use Hydrastis canadensis as a case 
study for investigating how biochemometrics, a methodology that combines chemical and 
biological data using multivariate statistics, can be best used to identify synergists and 
additives in complex mixtures. 
The first goal was achieved by adapting a crude disk-diffusion assay where 
bacterial hyaluronidase degrades polymeric hyaluronan into disaccharide units, into a 
quenchable, small volume aqueous reaction in lo-binding tubes that could be directly 
 
 
analyzed via LC-MS. This method was validated by screening a known inhibitor of 
Streptococcus agalactiae hyaluronidase, ascorbic acid 6-palmitate, resulting in values 
within the same order of magnitude as literature reports. Instrumental method validation 
was also performed by evaluating repeatability, and intermediate precision, and 
determining the limit of detection and limit of quantification. This assay was then used to 
identify two fungal metabolites, leotiomycene A and leotiomycene B as the most potent 
Streptococcus agalactiae hyaluronidase inhibitors to date, and leotiomycene B as the first 
reported inhibitor of Staphylococcus aureus hyaluronidase. The concentrations at which 
these compounds inhibited hyaluronidase were found to not have any antimicrobial 
effects, and are therefore potential candidates for the development of anti-hyaluronidase 
treatments for Streptococcus agalactiae and Staphylococcus aureus infections. 
The second goal was achieved by creating a database of isolated Hydrastis 
canadensis constituents using LC-MS that included retention time, accurate mass in both 
polarities, and high mass accuracy fragmentation patterns in both polarities. The raw file 
for each pure compound was uploaded into the Global Natural Product Social Molecular 
Networking database for dereplication purposes and to facilitate open access data sharing. 
To evaluate the effectiveness of biochemometrics for identifying synergists and additives, 
an organic extract of aerial material from H. canadensis underwent various stages of 
fractionation. Each stage of resultant fractions was profiled using the previously 
described LC-MS method, and their ability to enhance the antimicrobial activity of 
berberine against S. aureus was evaluated. These data were uploaded into the program 
Sirius, where multivariate statistical analyses were applied to create selectivity ratio (SR) 
 
 
plots. Retention time-mass pairs with low SR values indicate that a specific compound 
correlates with the observed biological activity, and should therefore guide isolation 
efforts. It was found that three stages of sample purification were needed to obtain SR 
plots that correctly predicted known additives and synergists. Interestingly, a m/z that was 
not yet known to H. canadensis was predicted to be responsible for bioactivity, and upon 
isolation, structure elucidation and confirmatory testing, it was shown that the new 
flavonoid 3,3′-dihydroxy-5,7,4′-trimethoxy-6,8-C-dimethylflavone was indeed a 
synergist, thus showing that this workflow can be useful for understanding the complex 
biological activities of botanical medicines. 
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CHAPTER I 
INTRODUCTION 
 
 
History of Plants Used for Human Health 
 
 Plants have been used as medicine for human health since ancient times, with the 
first recorded evidence of usage dating back at least 5000 years ago via Sumerian clay 
slabs (1). Nature has provided many useful cures for disease since then; for instance, 
taxol, which is used today to treat ovarian, breast and non-small cell lung cancers, was 
discovered from the bark of the pacific yew tree (Taxus brevifolia) (2). The discovery of 
artemisinin and dihydroartemisinin from Artemisia annua, which is used to treat malaria, 
was due in part to Dr. Youyou Tu, who investigated traditional Chinese medicine to 
determine how to best prepare extracts (3). These studies led to her receiving the Nobel 
Prize in Physiology or Medicine in 2015. In fact, 146 of 174 anticancer drugs on the 
market from 1981 til 2014 were either derived from or inspired by compounds found in 
nature. In addition, 148 of 221 small molecule drugs have come from or inspired by 
nature, some of which were found by investigating traditional medicine (4). Botanicals 
play an important role in dietary supplements, with sales exceeding $7 billion in 2016 in 
the United States, with an increase of $530 million from the previous year (5). Hydrastis 
canadensis L. (Ranunculaceae), or goldenseal, is a common ingredient in dietary 
supplements that boast enhanced immunity, with most recent reports indicating that 
supplements containing both goldenseal and Echinacea were responsible for $6.68 
 
2 
 
million in the US in 2014, while goldenseal-only supplements had a total of $1.31 million 
in sales (6, 7). Goldenseal is a perennial herb native to the Appalachian Mountains that 
grows best in shaded, deciduous forests. Goldenseal thrives in soil with good water 
drainage and is commonly found growing alongside white oak trees, hickory trees, 
ginseng and mayapple (8). It has been used to treat a variety of ailments throughout 
history, with Native American tribes having prepared tonics from root material to treat 
digestive irritability and infections of the eyes and skin (9, 10). The effects that natural 
product mixtures have on biological systems are often attributed to the most abundant 
constituents. In the case of goldenseal, the isoquinoline alkaloids berberine and ß-
hydrastine, which account for 0.5-6 % and 1.5-4 % of plant material, respectively, were 
thought to be responsible for broad-spectrum bioactivity (6). Advances in 
chromatography, mass spectrometry and purification techniques have led to the discovery 
of not only more isoquinoline alkaloids and other biologically relevant compound classes 
within goldenseal, but has also allowed for the detection and identification of low-
abundance constituents that in fact contribute to bioactivity. This has been demonstrated 
where aerial extracts of goldenseal had more antimicrobial activity against the Gram 
positive pathogen Staphylococcus aureus than predicted based upon the concentration of 
berberine present in the tested extract (9, 11). It was determined via synergy-directed 
fractionation and follow-up testing that the enhanced antimicrobial activity of goldenseal 
aerial extracts is due to the presence of low abundance flavonoids (9). 
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The Problem of Antibiotic-resistant Infections & the Idea of Anti-virulence 
Targeting 
The development of antibiotic resistance by bacterial pathogens remains a 
worldwide health threat. It is estimated that in United States, antibiotic-resistant 
infections are responsible for over 2,000,000 hospitalizations and 23,000 deaths annually, 
while the annual estimated worldwide death toll surpasses 700,000 (12, 13). As the rate 
of resistance development continues to increase, the number of effective treatments 
decreases, as fewer pharmaceutical companies are pursuing antibiotic research due to 
lowered profitability, and as antibiotic resistance often encompasses entire compound 
classes (14, 15). Furthermore, there have been no new antibiotic compound classes 
discovered since 1987, constituting an ongoing discovery void (16). Many institutions 
and groups have recognized the promise of complementary and alternative approaches to 
ameliorating the burden of resistance development (17-20). One methodology, termed the 
“anti-virulence” approach, consists of targeting the mechanism of pathogenicity, as 
opposed to outright killing or inhibiting the growth of bacteria. As this method does not 
target essential pathways and therefore does not put selective pressure on the bacteria, it 
is thought to be exempt from resistance development. Research has been done to identify 
chemical entities that limit bacterial pathogenicity and virulence, although none have yet 
made it to the stage of clinical development (21). One of the challenges in finding anti-
virulence compounds is the lack of target-specific biological assays. As bacterial growth 
inhibition is not the target of anti-virulence treatments, other biological metrics must also 
be measured; for example, signaling, toxin production and spreading (22-25). These 
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specialized biological assays can involve the engineering of knock-out bacterial strains 
and the utilization of sensitive analytical techniques, one of being liquid chromatography 
coupled to mass spectrometry. 
 
Advantages of Mass Spectrometry to Facilitate Natural Product Research 
Ultra high pressure liquid chromatography coupled to high resolving-power mass 
spectrometry (UPLC-MS) has improved dereplication, which is the identification of 
known constituents earlier in fractionation process to better save time and resources. 
Although this technique has been used for some time, the shortening of chromatographic 
methods along with the addition of high mass accuracy measurements and fragmentation 
patterns has greatly improved this methodology. The benefit of the inclusion of accurate 
mass measurements and fragmentation patterns is that it allows for the differentiation of 
structural isomers when they happen to co-elute. Another advantage lies in the rapid 
detection of known constituents in understudied specimens like fungi, whose chemical 
profiles may not be annotated in the scientific literature. This workflow was successfully 
applied fungal extracts that possessed cytotoxic activity, resulting in the exclusion of 
approximately half of the extracts due to the presence of known cytotoxic compounds 
(26). Later, mass defect filtering was added to this pipeline, which is a post-acquisition 
data mining technique filters spectra for a certain windows of the nonintegral portion of 
the m/z (known as mass defect) to identify tentative structural analogues. This technique 
is based upon that fact that every compound has a defined mass defect, and is leveraged 
by the capability of high resolving-power mass spectrometers to measure mass to the 
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1000ths place (27). As the scientific community shifts to open-source data sharing, the 
desire for cloud-based fragmentation databases has grown, resulting in the development 
of the Global Natural Product Social Molecular Networking system (GNPS). Users can 
upload fragmentation data into the GNPS database, and could then upload their raw files 
into the cloud based software, which would then screen their data against the user-curated 
GNPS database along with others professionally-curated databases such as those 
provided by the National Institutes of Health, Pacific Northwest National Lab and 
Massbank. The results of this process are networks of m/z values that are connected based 
upon a measure of similarity between fragmentation patterns, as well as tentative 
structure identifications. Although this methodology does not include orthogonal 
measurements such as retention time, it does allow for the tentative identification of 
potentially new, structurally similar molecules to those present in the databases (28, 29). 
These advances in dereplication are a direct result of the utilization of LC-MS/MS.  
The quality of and confidence in biological measurements has increased since the 
inclusion of mass spectrometry. When working with natural product mixtures, it is often 
observed that interferences arise in spectrophotometric or optical density-based 
measurements. This was demonstrated by Brown et al. in an evaluation of bacterial efflux 
pump inhibition, where compounds with known activity were falsely negative in a 
fluorescence-based assay. A mass spectrometry-based bioassay was presented as a 
quantitative alternative, and resulted in the positive identification of known inhibitors 
what were seemingly inactive via the fluorescence assay (30). Further, the identification 
of quorum-sensing inhibitors in a quantitative manner was made possible by mass 
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spectrometry, where instead of using fluorescence methods which require engineered 
strains of bacteria and are prone to optical interferences. Staphylococcus aureus auto-
inducing peptide, a marker of quorum-sensing, was directly measured in filtered spent 
broth to quantify. This method was validated by screening a known inhibitor, which 
resulted in an IC50 value that matched with previous literature reports (23). 
Lastly, the application of multivariate statistics into discovery workflows has 
enhanced the informative power of mass spectral measurements and the ability of 
researchers to efficiently prioritize leads. One challenge of using large mass spectrometry 
data sets is the propensity to only analyze positive data; for example, when an extract or 
fraction is determined to be of interest based upon a biological measurement, its chemical 
profile is often investigated, while the chemical profiles of inactive or less-active samples 
are ignored. The inclusion of “negative” data is advantageous in that it sheds light on 
which constituents are not relevant to biological activity. When multiple samples are 
profiles, sometimes in both polarities, the amount of data acquired can become 
overwhelming to the point where the individual evaluation of each piece of data becomes 
cumbersome and inefficient (31). The application of multivariate statistics to mass 
spectrometry datasets has enabled rapid identification of chemical signals that influence 
similarity and dissimilarity between samples, which can be used to pinpoint markers of 
disease or the instance of sample adulteration (32-34). Another challenge in managing 
these datasets comes from the incorporation of biological data measurements, which 
serve as an orthogonal measurement of similarity between samples. The application of 
multivariate statistics has proven successful in determining which constituents in 
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complex mixtures are important for certain applications, and has therefore been shown to 
be an advantageous addition to mass spectrometry-based research (32, 35-40). 
 
Research Goals 
The studies herein have two differing but important foci; the creation and use of a 
mass spectrometry-based bioassay to discover compounds that limit bacterial virulence 
by inhibiting spreading, and the integration of mass spectrometry and biological 
measurements via multivariate statistics to identify additives and synergists in complex 
mixtures (Hydrastis canadensis). The common thread between both is the pursuance of 
knowledge via mass spectrometry as to how natural product medicines can be used to 
treat infections.  
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CHAPTER II 
A NEW MASS SPECTROMETRY BASED BIOASSAY FOR THE DIRECT  
ASSESSMENT OF HYALURONIDASE ACTIVITY AND INHIBITION 
 
 
This chapter has been published in the Journal of Microbiological Methods and is 
presented in that style. Britton, E.R., Ibberson, C.B., Horswill, A.R., Cech, N.B. J. 
Microbiol Methods. 2015, 119, 163-167. 
 
 
Britton, E.R. developed the hyaluronidase assay, collected all data and wrote the 
manuscript. Ibberson, C.B. provided preliminary data that prompted the 
development of the assay, isolated hyaluronidase from Staphylococcus aureus, 
described the procedure in the Materials and Methods section, and provided edits 
on the manuscript.  
Horswill, A.H. made experimental suggestions, provided guidance and made edits 
on the manuscript. Cech, N.B. provided suggestions and edits throughout 
manuscript preparation. 
 
 
Introduction 
 The development of resistance by bacterial pathogens is a growing threat (12). 
The overuse of antibiotics accelerates resistance development, and there is an urgent need 
for alternative therapeutic strategies against bacterial infections (41). One potential 
alternative target is hyaluronidase, a virulence factor secreted by Gram-positive bacterial 
pathogens such as Staphylococcus aureus (42) and Streptococcus agalactiae (43, 44). 
Both of these pathogens are considered by the Centers for Disease Control to be of 
concerning and serious threat for resistance development (12). Hyaluronidase degrades 
hyaluronan, a polymer found in the skin and other tissues. The resulting disaccharide 
product serves as an energy source for the bacteria, enabling the infection to spread 
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through tissues (43, 45). Thus, anti-virulence therapeutic agents could be developed 
against bacterial infections by specifically targeting hyaluronidase (42, 43, 46).  
Only a few studies have investigated the inhibition of hyaluronidase by chemical 
means. It has been shown that ascorbic acyl 6-palmitate and other vitamin C derivatives 
have low micromolar potency against Streptococcus pneumoniae and Streptococcus 
agalactiae hyaluronidases (47, 48). These studies show the potential of hyaluronidase 
inhibition as a therapeutic target. Further efforts towards the identification and 
development of more potent hyaluronidase inhibitors will require a robust screening 
assay that provides quantitative comparisons of inhibitor potency.  
Several methods have been developed to measure the activity of the 
hyaluronidase enzymes. Qualitative measurements can be obtained using agar plate 
assays. These assays rely on measuring clearance zones in solid media containing 
hyaluronan after addition of the hyaluronidase enzyme (42, 49, 50). More quantitative 
measurements can be obtained using spectrophotometric approaches, which rely on a 
reaction between the disaccharide and a substrate that in turn produces a colored product 
(51). For example, the Morgan-Elson reaction employs the transformation of the N-acetyl 
glucosamine reducing end of the disaccharide to a series of products using varied pH and 
temperature environments. The final product is subsequently reacted with p-
dimethylaminobenzaldehyde to produce a red complex that can be detected by 
monitoring absorbance at 585 nm (52). This method was improved upon by measuring 
fluorescent intensity after excitation at 545 nm, resulting in an increase in sensitivity (51). 
Finally, turbidimetric measurements can be utilized to assess hyaluronidase inhibition, in 
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which hyaluronidase is incubated with hyaluronan, and subsequently treated with 
cetylpyridinium to precipitate undigested hyaluronan. An increase in light transmittance 
correlates with increasing disaccharide concentration (50). The aforementioned assays 
have important utility. For example, agar based assays and turbidimetric measurements 
can serve as a simple preliminary screen to identify potential inhibitors, and 
spectrophotometric assays have demonstrated utility for measuring enzyme kinetics 
parameters (53). However, the inherent indirect nature of these assays means that they are 
time-consuming and subject to interference. Our laboratory has designed an assay that 
utilizes mass spectrometry to reproducibly measure the production of disaccharides by 
hyaluronidase enzymes. In contrast to spectrophotometric techniques, our design requires 
fewer steps. The new assay is also sensitive and robust, providing excellent repeatability 
from assay to assay, even across multiple days. Here we present the new methodology 
and show its applicability to measuring the activity of hyaluronidase inhibitors. 
Materials and Methods 
Purification of S. aureus hyaluronidase 
 To generate the hyaluronidase overexpression construct pCR03, the hysA gene 
without the encoded signal sequence was amplified from AH1263 genomic DNA using 
primers CBR41 (5’GTTGTTGCTAGCGATACGAATGTTCAAACGCCAG3’) and 
CBR42 (5'GTTGTTCTCGAGGTGTCGAGATTTTCTTGCATT3'), which contain NheI 
and XhoI sites at their 5’ ends, respectively (42). The resulting PCR product was ligated 
into pET28a linearized with NheI and XhoI and electroporated into E. coli strain ER2566 
to generate strain AH2856. To purify hyaluronidase, AH2856 was grown overnight at 
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37°C in luria broth (LB) (Sigma, St. Louis, MO) containing kanamycin (50 μg/mL), and 
subcultured into 1 L of fresh LB at a ratio of 1:250. The culture was grown at 30°C to 
mid-logarithmic phase, IPTG was added to 1 mM final concentration, and the culture was 
allowed to grow for an additional 4 h. Cells were harvested by centrifugation, washed 
once with water, pelleted by centrifugation, and frozen at -20°C. Cells were mechanically 
lysed by two passages through a Microfluidics Microfluidizer model LV1 (Newton, MA) 
at 25,000 psi. Cell lysate was clarified by centrifugation for 20 min at 15,000  g at 4 °C. 
Protein was purified in the presence of 1 mM Tris(hydroxypropyl)phosphine (THP) using 
Fractogel His-Bind Resin (EMD Millipore, Darmstadt, Germany) as per the 
manufacturer’s instructions. The protein was dialyzed into phosphate buffered saline 
(PBS) containing 1 mM THP, concentrated using Millipore Centrifugal Filter Unit 
(Temecula, CA, 30,000 molecular weight cut-off), and brought to 10 mg/mL in 1X PBS 
containing 1 mM THP. The protein suspension was frozen in 20% glycerol at -20°C until 
use. 
Bioassay procedure 
 Concentrated stock solutions of hyaluronidase from S. agalactiae (R & D 
Systems, Minneapolis, MN) and S. aureus (isolated as described in 2.1) were prepared 
with PBS with 10% glycerol and stored at -80°C in Lo-binding Eppendorf tubes. 
Aliquots were thawed at room temperature and diluted with PBS to a concentration of 
1.25 μg/mL. A stock solution of hyaluronic acid sodium salt from Streptococcus equi 
(Sigma, St. Louis, MO) was prepared at 5 mg/mL with deionized water (EMD Millipore, 
Temecula, CA). To each Lo-binding Eppendorf tube, 1.25 μg/mL hyaluronidase and 1 
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mg/mL extract in dimethylsulfoxide (DMSO) were added and incubated at 37°C. After 
incubation, 5 mg/mL hyaluronan was added to each tube and thoroughly mixed before 
incubation at 37°C for 15 min. and shaking at 400 rpm. The final assay concentrations of 
hyaluronidase, extract and hyaluronan were 0.61 μg/mL, 24.4 μg/mL and 2.44 mg/mL, 
respectively. To quench the reaction, an aliquot from the reaction mixture was diluted 50-
fold with acetonitrile (Fisher Scientific, Pittsburgh, PA) containing 0.1% formic acid 
(Fisher Scientific, Pittsburgh, PA). The diluted reaction was then submitted to 
ultraperformance liquid chromatography-mass spectrometry (UPLC-MS) analysis via a 
Waters Acquity UPLC with an Acquity UPLC column (BEH HILIC, 1.7 μm, 2.1 x 50 
mm, Waters Corporation, Milford, MA) and a Thermo Quantum Access triple stage 
quadrupole (TSQ) mass spectrometer with electrospray ionization source (Thermo Fisher 
Scientific, MA, USA). Ascorbic acyl 6-palmitate (also referred to as ascorbic acid 6-
palmitate) (Sigma, St. Louis, MO) served as the positive control. The identity of the 
disaccharide (3-(4-deoxy-β-D-gluc-4-enuronosyl)-N-acetyl-D-glucosamine,  Figure 1) 
was confirmed by accurate mass measurements (Thermo LTQ Orbitrap, Thermo Fisher 
Scientific, MA, USA), its absence in assays with inactive enzyme, and by comparison 
with a standard (Carbosynth, UK). The Thermo LTQ Orbitrap was operated at the 
following settings: spray voltage, 4000 V; sheath gas, ion sweep gas, and auxiliary gas 
pressure, 30, 0, and 20, respectively; capillary temperature, 300°C; tube lens offset, 100 
V. 
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ESI-MS analysis 
Hyaluronan was degraded by S. agalactiae hyaluronidase and used to optimize 
MS settings. All solvents used in the present study were Optima LC-MS grade (Fisher 
Scientific, Pittsburgh, PA). Diluted reaction mixtures (3 µL) were eluted from the column 
at a flow rate of 0.2 mL/min using the following binary gradient with solvent A 
consisting of water with 0.1% formic acid additive and solvent B consisting of 
acetonitrile with 0.1% formic acid additive. The gradient initiated at an isocratic 
composition of 15:85 (A:B) for 1.5 min., increasing linearly to 100:0 (A:B) from 1.5 to 
2.5 min., followed by an isocratic hold at 100:0 (A:B) from 2.5 to 4.4 min., gradient 
returned to starting conditions of 15:85 (A:B) from 4.4 to 4.5 min., and was held from 4.5 
to 5 min. The Thermo Quantum Access triple stage quadrupole mass spectrometer was 
operated at the following settings: spray voltage, 4000 V; vaporizer temperature, 384°C; 
sheath gas, ion sweep gas, and auxiliary gas pressure, 60, 2.0, and 5, respectively; 
capillary temperature, 202°C; tube lens offset, 181 V. 
Percent inhibitions were based on a comparison of relative peak areas associated 
with the protonated m/z of the disaccharide units. Standard error was calculated for each 
triplicate set of measurements, and IC50 values were calculated using a four parameter 
logistic standard curve analysis function in SigmaPlot (v12.5).  
 
 
 
Figure 1. Reaction Between Hyaluronan Polymer and Hyaluronidase. 3-(4-deoxy-β-D-gluc-4-
enuronosyl)-N-acetyl-D-glucosamine units are produced via β elimination of the 1→4 glycosidic bond. 
 
14 
 
Method validation for the detection of 3-(4-deoxy-β-D-gluc-4-enuronosyl)-N-acetyl-
D-glucosamine 
A stock solution of 3-(4-deoxy-β-D-gluc-4-enuronosyl)-N-acetyl-D-glucosamine 
(99% pure, Carbosynth, West Berkshire, UK) was serially diluted to make seven 
concentrations of 0.78, 1.6, 3.1, 6.2, 12.5, 25 and 50 µM. A calibration curve was 
generated using the UPLC-MS as described above, and the log of the peak areas of the 
selected ion chromatograms for 3-(4-deoxy-β-D-gluc-4-enuronosyl)-N-acetyl-D-
glucosamine ions were plotted versus the log of the concentration. 
 Method validation was conducted according to the guidelines of the International 
Committee of Harmonisation (ICH) section Q2 (R1) (54) with external calibration 
curves. The linear dynamic range was determined by analyzing samples ranging in 
concentration from 0.39 to 500 µM. Repeatability was evaluated by analyzing the seven 
standards that fell within the linear range (0.78-50 µM) in triplicate and determining the 
standard deviation and relative standard deviation of the back-calculated 3-(4-deoxy-β-D-
gluc-4-enuronosyl)-N-acetyl-D-glucosamine concentration for those analyses. 
Intermediate precision was evaluated by conducting the repeatability study three times on 
three different days. The standard deviation and relative standard deviation for the 
intermediate precision were calculated using the average back-calculated concentration 
for each of the three days for each standard concentration. Limit of detection (LOD) was 
defined as the lowest concentration of 3-(4-deoxy-β-D-gluc-4-enuronosyl)-N-acetyl-D-
glucosamine that provided a signal-to-noise ratio of 3. Limit of quantitation (LOQ) was 
defined as the lowest concentration that provided a residual of less than 15%.  
 
15 
 
Results 
Activity of S.agalactiae and S. aureus hyaluronidases  
 We first sought to confirm the ability to detect the disaccharide product ( Figure 
1) produced by action of hyaluronidase on the hyaluronan polymer. LC-MS analysis of 
the reaction mixture in which S. agalactiae or S. aureus hyaluronidase enzymes were 
incubated with hyaluronan resulted in production of two slightly resolved ions detected 
with m/z 380.1192. The identity of the ions as products of hyaluronidase was supported 
by their observed loss after boiling the S. aureus and S. agalactiae reaction mixtures to 
deactivate the enzyme (Figure 2). Additional confirmation was provided by 
measurements with high resolving power mass spectrometry, in which the observed mass 
of the observed ions (380.1182) matched the calculated monoisotopic mass for 
protonated 3-(4-deoxy-β-D-gluc-4-enuronosyl)-N-acetyl-D-glucosamine (380.1192) to 
within 2.6 ppm. Finally, we monitored time-dependent production of the disaccharide 
products (Figure S1), and determined that disaccharide production increased over the 
range of 10 to 60 min. Thus, 15 min was chosen as the incubation time for the reactions.  
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Figure 2. Selected Ion Chromatograms Representing Two Parallel Hyaluronidase Bioassays. A 
reaction performed with 0.61 µg/mL S. agalactiae hyaluronidase and 2.44 mg/mL hyaluronan is shown in 
panel (A), and another reaction with identical conditions except that the enzyme was boiled for 15 min. 
prior to incubation is shown in (B). The experiment performed under the same conditions using active and 
denatured S. aureus hyaluronidase is shown in panels C and D, respectively. Peaks for m/z 380.0 were 
observed at 1.3 min for the active enzyme (A, C), and not for the denatured hyaluronidase (D, E). The 
experiment was performed in triplicate and the same results in the representative chromatograms above 
were observed for all replicates. NL indicates the level of signal (counts detected by the mass spectrometer) 
used to normalize each chromatogram.  
 
Use of the HILIC-ESI-MS assay to evaluate inhibition  
 We also endeavored to evaluate the effectiveness of the method demonstrated in 
Section 3.1 to monitor enzyme inhibition. Ascorbic acyl 6-palmitate (compound 1, Figure 
3), has a published IC50 value of 4 μM against S. agalactiae hyaluronidase (47). This 
literature value is in agreement with the IC50 value of 8.0 ± 1.0 μM that was measured for 
a dose-response study of hyaluronidase inhibition by ascorbic acyl 6-palmitate monitored 
with UPLC-MS detection (Figure 4A). On the basis of structural similarity to ascorbic 
acyl 6-palmitate, we predicted that n-cyclohexanecarbonylpentadecylamine (Cayman 
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Chemical, Ann Arbor, MI, compound 2,  Figure 3) would also act as a hyaluronidase 
inhibitor. This compound was also observed to inhibit the activity of hyaluronidase, 
although with somewhat less potency (IC50 30.4 ± 9.8 μM,  Figure 4).  
 
 
 
 Figure 3. Ascorbic acyl 6-palmitate (1) and n-cyclohexanecarbonylpentadecylamine (2). 
 
 
 
 
 
Figure 4. Dose Response Curves of Streptococcus agalactiae Hyaluronidase Versus Compounds 1 (A) 
and 2 (B). Panel A represents a dose response curve of S. agalactiae hyaluronidase versus ascorbic acyl 6-
palmitate (conditions identical to  Figure 2A). The measured IC50 was 8.0 ± 1.0 μM. Panel B represents a 
dose response curve of S. agalactiae hyaluronidase versus n-cyclohexanecarbonylpentadecylamine, for 
which the IC50 was 30.4 ± 9.8 μM. Each data point is an average of triplicate measurements of disaccharide 
peak area, with error bars corresponding to standard error.  
 
Method validation 
 A number of parameters were measured to validate the new method. From these 
validation studies, the linear dynamic range was determined to be from 0.78 to 50 µM 3-
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(4-deoxy-β-D-gluc-4-enuronosyl)-N-acetyl-D-glucosamine (Table 1). A calibration 
curve generated over this concentration range had a correlation coefficient of 0.997. With 
the new method, the limit of detection (LOD) and limit of quantitation (LOQ) were 0.29 
µM and 0.78 µM 3-(4-deoxy-β-D-gluc-4-enuronosyl)-N-acetyl-D-glucosamine, 
respectively. The LOD reported here lower than that reported by Reissig et al. using the 
Morgan-Elson colorimetric assay (1955). These investigators reported a limit of detection 
of 3 x 10
-10
 moles of N-acetyl-D-glucosamine (the reducing end of the disaccharide 
product), which is equivalent to 1.32 µg/mL N-acetyl-D-glucosamine or 6.0 µM 3-(4-
deoxy-β-D-gluc-4-enuronosyl)-N-acetyl-D-glucosamine. The LOD for the fluorometric 
version of the Morgan-Elson assay described by Takahashi et al. (2003) was 0.016 
µg/mL N-acetyl-D-glucosamine, equivalent to 0.071 µM 3-(4-deoxy-β-D-gluc-4-
enuronosyl)-N-acetyl-D-glucosamine. This limit of detection is approximately 4 times 
lower than the LOD reported here. Thus, the new mass spectrometric assay appears to be 
more sensitive than the published colorimetric assay, but less sensitive than the 
fluorometric assay.  
As a measure of the accuracy of the new method, the back calculated 
concentrations of the standards (residuals) differed from their nominal concentrations by 
≤ 11% across the linear dynamic range (Table 2). The new method also demonstrated 
excellent precision. As evidence of this, the relative standard deviation values for both 
repeatability (precision between injections) and intermediate precision (precision across 
multiple days) were less than or equal to 10% (Table 2).  
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Table 1. Regression Parameters, Detection Limit, and Limit of Quantification  
for 3-(4-deoxy-β-D-gluc-4-enuronosyl)-N-acetyl-D-glucosamine 
 
Validation parameter Resulta 
Correlation coefficient 0.997 
Standard error 0.040 
y-Intercept 5.886 ± 0.025 
Slope of regression line 1.006 ± 0.025 
Number of data points 21 
Limit of detection (LOD) 0.29 µMb 
Lower limit of quantitation (LLOQ)  0.78 µMc 
Upper limit of quantitation (ULOQ)  50 µM 
a Calculations were based on triplicate analyses of seven standards of  
3-(4-deoxy-β-D-gluc-4-enuronosyl)-N-acetyl-D-glucosamine using UPLC-MS. 
b LOD was defined as the concentration that provided a signal to noise ratio of  
3:1 with noise determined by injection of a solvent blank (acetonitrile with 0.1% 
formic acid). 
c LOQ was defined as the lowest concentration of standard in the calibration  
curve that provided a residual of less than 15% (Table 2). 
 
 
Table 2. Precision Data for 3-(4-deoxy-β-D-gluc-4-enuronosyl)-N-acetyl-D-glucosamine 
 
Theoretical 
concentration (µM) 
Measured 
concentrationa (µM) 
Residualsb (%) Repeatabilityc (%) Intermediate 
precisiond (%) 
0.78 0.82 5 2 10 
1.6 1.4 -11 7 6 
3.1 3.2 1 2 4 
6.2 6.2 0 2 10 
12.5 13.8 10 3 4 
25 27 7 5 5 
50 46 -7 5 7 
a The measured concentration is an average of back calculated concentration of 3-(4-deoxy-β-D-gluc-4-
enuronosyl)-N-acetyl-D-glucosamine obtained from triplicate analyses on three different days. 
b (Measured concentration-theoretical concentration) / theoretical concentration x 100. 
c Repeatability is expressed as the percentage relative standard deviation for triplicate analyses conducted 
on a single day. 
d Intermediate precision is expressed as the percentage relative standard deviation of the three back-
calculated 3-(4-deoxy-β-D-gluc-4-enuronosyl)-N-acetyl-D-glucosamine concentrations (each an average of 
triplicate measurements) determined on three separate days. 
 
Discussion 
Mass spectrometric analysis of sugars in biological matrices has often been 
complicated by the high polarity of these compounds, which prevents their retention on 
the reversed phase C-18 columns that are commonly employed for LC-MS analyses (55). 
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With this study, we employed instead hydrophilic interaction liquid chromatography 
(HILIC), a chromatographic approach that has recently gained popularity for the analysis 
of polar species (55, 56). The application of HILIC enabled the disaccharide product to 
be retained effectively (1.4 min, Figure 2, panels A and C). This product was not retained 
with reverse phase chromatography (data not shown). Using HILIC coupled to mass 
spectrometry, it was possible to quantitatively monitor the activity of the hyaluronidase 
enzyme, and to replicate the published IC50 value of a known hyaluronidase inhibitor. 
Unlike previously published spectrophotometric methods (50, 51), the new MS based 
assay directly measures the product of the enzyme. Another advantage of this approach is 
that it will not be subject to interference by compounds that absorb or scatter light. Thus, 
although it is somewhat less sensitive than the published fluorometric method, it could be 
a useful alternative approach for situations where interference is observed with 
fluorometric analyses.  
The detection of two ions in the active enzyme cultures was unexpected. These 
ions were partially resolved chromatographically (Figure 2), which indicates that they are 
both present in the solution prior to analysis, and not an artifact of analysis by the mass 
spectrometer. Given that both of these ions match the predicted mass of the 3-(4-deoxy-β-
D-gluc-4-enuronosyl)-N-acetyl-D-glucosamine product, it is presumed that they are 
isomers of the same molecule. The configuration of these isomers could not be confirmed 
with mass spectrometry, however, their presence and absence, respectively, in mixtures 
with and without active enzyme made them a useful product on which to base the 
biological assay.  
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Numerous pathogenic bacteria secrete hyaluronidase, including Staphylococcus 
aureus, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus pneumoniae, 
Peptostreptococcus, Streptomyces, Clostridium, and Propionibacterium (46). 
Hyaluronidases from S. agalactiae, S. pneumoniae and S. aureus have been found to have 
a high degree of homology, with greater than 35% amino acid identity across the entire 
enzyme and complete conservation of catalytic residues (46, 47). Thus, it is possible that 
a hyaluronidase inhibitor could have broad-spectrum activity against multiple pathogens 
that secrete hyaluronidase. Therapeutic agents targeting hyaluronidase would have the 
advantage of selectively targeting pathogenic bacteria, leaving beneficial bacterial flora 
intact (46). The bioassay developed here could enable screening for new hyaluronidase 
inhibitors against a range of bacteria pathogens, and, as such, could contribute 
importantly towards the development of new therapies based on hyaluronidase inhibition.  
Conclusion 
This work demonstrates the effectiveness of a mass spectrometric method for 
monitoring activity and inhibition of hyaluronidase. Here we employed the assay to 
monitor activity of S. aureus and S. agalactiae hyaluronidases, and to identify a new 
hyaluronidase inhibitor (n-cyclohexanecarbonylpentadecylamine). Future studies could 
employ this mass spectrometric approach in more extensive screening efforts, or to study 
enzyme kinetics. 
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CHAPTER III 
 
FUNGAL METABOLITE INHIBITORS OF HYALURONIDASE,  
THE STAPHYLOCOCCUS AUREUS 
SPREADING FACTOR 
 
 
This chapter has been prepared for submission to the journal Antimicrobial 
Agents and Chemotherapy and is presented in that style. Britton, E.R., Stempin, 
J.J., Paguigan, N.D., Augustinovic, M., Raja, H.A., Horswill, A.H., Oberlies, 
N.H., Cech, N.B. Antimicrob. Agents Chemother. In preparation. 
 
Britton, E.R. performed and interpreted all antimicrobial assay data, analyzed and 
prepared hyaluronidase assay data, created all of the figures and wrote the 
manuscript. Stempin, J.J. ran all of the hyaluronidase assays and provided 
organized data for interpretation. Paguigan, N.D. isolated the leotiomycene 
compounds and provided them for testing. Augustinovic, M. isolated and 
provided additional leotiomycene A and B for testing. Raja, H.A. grew the fungi 
from which the leotiomycenes were isolated. Horswill, A.H. and Oberlies, N.H. 
made experimental suggestions, provided guidance and made edits on the 
manuscript. Cech, N.B. provided suggestions and edits throughout manuscript 
preparation. 
 
Introduction 
Approximately 700,000 people die each year from drug resistant infections 
worldwide, and it is predicted that the death toll will surpass 10 million by the year 2050, 
which exceeds the current number of annual deaths caused by cancer (13). An estimated 
2 million people in the United States acquire antibiotic resistant infections annually, 
resulting in 23000 deaths (12). Methicillin-resistant Staphylococcus aureus infections, 
which are considered to pose a great risk to human health by the WHO, are the most 
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common of cause of these, accounting for almost 50% (12, 57). Few treatments are 
available to treat these problematic infections, and the pipeline for new antibiotics is 
lacking in leads, which could lead to an era where once-treatable infections will again 
become lethal (12). Therefore, it is of critical concern that alternative methods to treat 
drug resistant infections are explored.  
 One potential alternative approach is targeting bacterial virulence. Virulence 
factors are the toxins produced by bacteria that facilitate the spread and pathogenicity of 
infection. It is possible that blocking the pathogenicity of the bacteria could result in 
decreased severity of infection. Ambuic acid and -hydroxyemodin, both of which are 
secondary metabolites produced by fungi, have been shown to mediate pathogenicity by 
blocking the communication of bacteria via quorum sensing (58, 59). Both have 
demonstrated efficacy in the treatment of skin infections in mouse models (58, 59). 
Another potential anti-virulence therapeutic target is the spreading factor hyaluronidase, 
employed by some pathogenic Gram-positive bacteria to facilitate the spread of infection 
(42, 46, 60, 61). Hyaluronidase is an exo-enzyme that degrades hyaluronan, a large 
glycosaminoglycan found in the extracellular matrix of mammalian soft connective 
tissue, into disaccharide units. The degradation of hyaluronan allows for the penetration 
of host tissue while providing a source of carbon for the bacteria (25, 43, 45, 62). As 
hyaluronan plays a role in wound healing and tissue turnover, its degradation by bacterial 
hyaluronidase further complicates healing (61). Furthermore, bacterial hyaluronidases 
also break down host-created hyaluronan fragments into disaccharides that can no longer 
function as pro-inflammatory and immune-stimulatory activators of toll-like receptors, 
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thus aiding in evasion of the immune system (63). It has also been shown that bacteria 
secrete hyaluronidase within biofilms, and this is proposed to facilitate dispersion and 
dissemination of bacteria into surrounding tissue (64). The essential role of hyaluronidase 
in bacterial virulence supports the investigation of inhibitors of this enzyme as alternative 
therapeutics for the treatment of infections. 
 To date, several inhibitors of hyaluronidase from Streptococcus agalactiae have 
been identified. L-ascorbic acid was found to have modest levels of inhibition, and after 
molecular docking and synthetic studies, L-ascorbic acid 6-palmitate was shown to be 
more potent due to an increase in hydrogen bonding events within the binding site, 
resulting in an IC50 of 4 M (47, 65). Later synthetic studies identified that longer alkyl 
chains increased potency, resulting in the identification of ascorbic acid 6-O-
octadecanoate as the most potent Streptococcus agalactiae hyaluronidase inhibitor to 
date, with an IC50 of 0.9 M (48). Benzimidazole and benzoxazole-2-thione derivatives 
were also identified to have inhibitory activity with IC50 values as low as 5 M (66). 
Carotenoids, flavonoids and triterpenes also have inhibitory activity, albeit much less 
potent than previously identified active compounds (67, 68). When using a new, mass 
spectrometry-based hyaluronidase screening assay, the activity of ascorbic acid 6-
palmitate (1) was confirmed against Streptococcus agalactiae hyaluronidase (IC50 of 8 
M) and n-cyclohexanecarbonylpentadecylamine was identified to have anti-
hyaluronidase activity, with an IC50 of 30.4 M (24). To date, there are no published 
inhibitors of Staphylococcus aureus hyaluronidase, although the mass spectrometry based 
assay does have the capability to screen against this enzymatic target (24). With this 
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project, our goal was to identify small molecule fungal metabolites effective at inhibiting 
hyaluronidase from both Streptococcus agalactiae and Staphylococcus aureus.  
Results and Discussion 
 The fungal metabolites -hydroxyemodin (3) and leotiomycene A-C (4-6) were 
evaluated for activity, which have been previously identified as having anti-virulence 
activity via inhibition of quorum sensing in Staphylococcus aureus (69). Compounds 7-9, 
synthetic modifications of 4, were also evaluated for inhibition. Inhibition of 
hyaluronidase from both Streptococcus agalactiae and Staphylococcus aureus was 
evaluated for each compound (Figure 5) at high and low concentrations to prioritize hits. 
Ascorbic acid 6-palmitate (1) served as the positive control for experiments using 
hyaluronidase from Streptococcus agalactiae, as there are no published inhibitors of 
Staphylococcus aureus hyaluronidase.  
 
 
 
Figure 5. Fungal Metabolites Tested Against Both Streptococcus agalactiae and Staphylococcus 
aureus Hyaluronidase. Ascorbic acid 6-palmitate (1) inhibits hyaluronidase from Streptococcus 
agalactiae and served as a positive control. -hydroxyemodin (3) is a fungal metabolite that inhibits 
quorum sensing in Staphylococcus aureus. Leotiomycene A-C (4-6) are fungal metabolites isolated from 
Leotiomycetes sp. The last three compounds (7-9) are synthetic analogues made from 4. 
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Leotiomycene A (4) and B (5) completely inhibited Streptococcus agalactiae 
hyaluronidase at both 60 and 6 M, making them more potent than the positive control, 
which inhibited hyaluronidase by 84.1% at 6 M, consistent with the literature (Figure 
6). -hydroxyemodin (3) was less potent, and inhibited hyaluronidase by 60.1% at 60 
M and 18.7 % at 6 M. Leotiomycene C (6) and the synthetic derivatives were inactive.  
 
 
 
Figure 6. Percent Inhibition of Hyaluronidase From Streptococcus agalactiae at 60 and 6 M. 
Ascorbic acid 6-palmitate served as the positive control, and the vehicle consisted of DMSO. Error bars 
represent the standard error of triplicate measurements. 
 
 
The IC50 of both compounds 4 and 5 against Streptococcus agalactiae 
hyaluronidase were determined to be 0.57 ± 0.12 µM and 0.686 ± 0.027 µM, respectively 
(Figure 7), making these the most potent inhibitors of Streptococcus agalactiae 
hyaluronidase to date. 
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Figure 7. Dose Response Curves of Leotiomycene A (4) and B (5) Against Hyaluronidase from 
Streptococcus agalactiae. IC50 and standard error was determined using a four-parameter logistic curve 
function in SigmaPlot (v 13). 
 
Because the anti-virulence strategy consists of blocking bacterial pathogenesis 
instead of killing the bacteria, growth inhibition of both compounds 4 and 5 was 
evaluated against Streptococcus agalactiae (COH1). The minimum inhibitory 
concentration (MIC) of both was 5 µM, and there was no growth inhibition at the 
concentrations at which these compounds inhibited hyaluronidase (Figure 8). 
 
 
 
Figure 8. Dose Response Curves of Compounds 4 and 5 Against Streptococcus agalactiae (Panel A). 
Levofloxacin served as the positive control (Panel B), resulting in a MIC of 6.9 µM, consistent with 
literature reports. 
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When the same compounds were screened against Staphylococcus aureus 
hyaluronidase, compound 5 was the most potent, with 100 % and 53.9 % inhibition at 61 
µM and 6 µM, respectively (Figure 9). Compound 4 was less potent, with 60.3 % and 
29.7 % inhibition at 61 µM and 6.1 µM, respectively. The synthetic derivatives (7-9) had 
slightly higher potency, but not enough to warrant further studies, and compound 3 was 
inactive. 
 
 
 
Figure 9. Percent Inhibition of Hyaluronidase from Staphylococcus aureus at 61 and 6.1 M. No 
positive control was used, and the vehicle consisted of DMSO. Error bars represent the standard error of 
triplicate measurements. 
 
Dose response curves were created to determine the IC50 for both compounds 4 
and 5. Compound 4 did not achieve complete inhibition (data not shown), and compound 
5 had an IC50 of 8.93 ± 0.41 μM (FIG 6). 
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Figure 10. Dose Response Curve of Compound 5 Against Hyaluronidase from Staphylococcus aureus. 
IC50 and standard error was determined using a four-parameter logistic curve function in SigmaPlot (v 13). 
 
 
Compound 5 was evaluated and found to possess no antimicrobial activity against 
Staphylococcus aureus (MRSA, USA300 LAC strain AH1263) (70, 71). Therefore, 
compound 5 would not inhibit the growth of bacteria at the concentration required to 
inhibit spreading. 
 
 
 
Figure 11. Dose Response Curves of Compounds 4 and 5 Against Staphylococcus aureus (Panel A). 
Berberine served as the positive control (Panel B), resulting in a MIC of 446 µM, consistent with literature 
reports (72). 
 
Presumably, the carboxylic acid moiety found in compounds 4 and 5 is required 
for activity against Streptococcus agalactiae hyaluronidase, as compounds 3 and 7-9 did 
not have inhibitory activity and did not have a carboxylic acid group. Furthermore, the 
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activity of compound 5 against Staphylococcus aureus hyaluronidase may be due in part 
to the increased flexibility of the molecule, as the center ring is opened and rotatable, 
while the other tested compounds have a closed center ring. Further studies could include 
the preparation of derivatives of compound 5 to find more potent Staphylococcus aureus 
hyaluronidase inhibitors and to investigate structure/function relationships. 
The discovery of leotiomycene A and B (4 and 5) as inhibitors of bacterial 
hyaluronidases opens the door for the discovery of more inhibitors. Compounds 4 and 5 
show potent anti-hyaluronidase activity while exhibiting no antimicrobial activity against 
Streptococcus agalactiae, and could therefore serve as a launching point for in vivo 
studies, as they are the most potent inhibitors to date. Current reports state that 
Streptococcus agalactiae infections are routinely treated by penicillin, and that some 
isolates have been shown to be resistant to tetracycline, erythromycin, ciprofloxacin, 
chloramphenicol and clindamycin. This is problematic for patients that have penicillin 
allergies, as clindamycin is often used as a next-in-line treatment. It is possible that early 
development of alternative, anti-virulence-based therapeutics could prevent resistance 
from occurring as rapidly, which could be of use for patients with allergies that rely on 
the use of non-penicillin-based therapeutics (73). 
Compound 5 has no in vitro antimicrobial activity against Staphylococcus aureus 
and is therefore an ideal candidate for further evaluation as an alternative therapeutic 
treatment. The basis of the anti-virulence approach is to limit pathogenicity and 
proliferation so that the host immune system can clear the infection on its own or in 
combination with existing antibiotics. There is evidence to support the phenomenon 
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where combination treatments are less likely to promote resistance development (74). 
Dual activity of compounds within one biological system indicate a lack of specificity 
which is required for relevant pharmaceutical drug leads (75). The activity of compound 
5 against Staphylococcus aureus hyaluronidase serves as a starting point for synthetic 
derivatization and the pursuit of hyaluronidase inhibitors from fungal sources. It is well 
known that fungi and bacteria communicate and compete for resources in the 
environment using small molecules (76). This is apparent in the case of compounds 4-6, 
which were isolated from fungi and possess anti-virulence activity against 
Staphylococcus aureus (58, 59, 69). Further support was shown here, with the anti-
virulence activity of bacterial spreading being inhibited by compounds 4 and 5. As many 
fungal species have yet to be investigated for their biological activity, they serve as a 
potentially rich source of hyaluronidase inhibitors. In conclusion, two new and potent 
inhibitors of Streptococcus agalactiae hyaluronidase have been identified and warrant 
further in vivo investigation. Also, the first inhibitor of Staphylococcus aureus 
hyaluronidase with modest potency has been identified, which can serve as a positive 
control for future studies as well as a starting place for structure-function and in vivo 
studies. As these compounds originated from fungi, future efforts to find anti-virulence 
compounds from fungi are justified. 
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Materials and Methods 
Culture media and test compounds 
 Müeller Hinton broth, defibrinated sheep blood, laked horse blood, levofloxacin, 
berberine, ascorbic acid 6-palmitate (1) and PBS were provided by Sigma Aldrich, (St. 
Louis, MO). Agar and solvents were purchased from Fisher Scientific (Pittsburgh, PA). 
Bacterial strains 
 Streptococcus agalactiae (COH1) is a highly virulent serotype III clinical isolate 
(77). Staphylococcus aureus (AH1263) is a USA300 community-acquired MRSA strain 
with induced erythromycin susceptibility (70, 71). 
Purification of S. aureus hyaluronidase 
 The details of this purification can be found in Britton et al., 2015.  
Hyaluronidase assay procedure 
  This assay was performed as described in Britton et al., 2015, with some minor 
modifications. A stock solution of hyaluronic acid sodium salt from Streptococcus equi 
(Sigma, St. Louis, MO) was prepared at 5 mg/mL with PBS (EMD Millipore, Temecula, 
CA). An aliquot from the reaction mixture was diluted 20-fold with acetonitrile (Fisher 
Scientific, Pittsburgh, PA) containing 0.1% formic acid (Fisher Scientific, Pittsburgh, 
PA) in order to quench the reaction and prepare for LC-MS analysis. The diluted reaction 
was then submitted to ultraperformance liquid chromatography-mass spectrometry 
(UPLC-MS) analysis via a Waters Acquity UPLC with an Acquity UPLC column (BEH 
HILIC, 1.7 μm, 2.1 x 50 mm, Waters Corporation, Milford, MA) and a Thermo Q-
Exactive Plus orbitrap mass spectrometer with electrospray ionization source (Thermo 
 
33 
 
Fisher Scientific, MA, USA). Ascorbic acid 6-palmitate (Sigma, St. Louis, MO) served as 
the positive control for experiments using hyaluronidase from Streptococcus agalactiae. 
Antimicrobial assay procedure 
MICs were determined as recommended by the Clinical Laboratory Standards 
Institute against clinically relevant strains of Streptococcus agalactiae (serotype III 
clinical isolate COH1) (77) and methicillin-resistant Staphylococcus aureus (MRSA, 
USA 300 LAC strain AH1263) (78). A single colony inoculum was grown to log phase in 
Müeller Hinton broth and adjusted to a final assay concentration of 1.0 × 10
5
 CFU/mL 
based upon absorbance at 600 nm (OD600). The negative control (vehicle) consisted of 
2% DMSO in broth, and the known antimicrobial compounds levofloxacin and berberine 
served as the positive controls for Streptococcus agalactiae and Staphylococcus aureus, 
respectively (79, 80). Wells were prepared in triplicate with all treatments and controls, 
and duplicate plates were made without bacteria for background absorbance subtraction. 
OD600 was read after 24 h for Streptococcus agalactiae and 18 h for Staphylococcus 
aureus, both at 37 °C using a Synergy H1 microplate reader (Biotek, Winooski, VT, 
USA). The MIC was defined as the concentration at which no statistically significant 
difference was observed between the negative control and treated sample. 
LC-MS analysis 
All solvents used were Optima LC-MS grade (Fisher Scientific, Pittsburgh, PA). 
Diluted reaction mixtures (7 µL) were eluted from the column using the chromatographic 
method found in Britton et al., 2015. The Thermo Q-Exactive Plus orbitrap mass 
spectrometer was operated in the positive polarity with the following settings: spray 
 
34 
 
voltage, 3700 V; capillary temperature, 350°C; sheath gas, 25; auxiliary gas, 5; and S 
lens level, 50. 
Percent inhibitions were based on a comparison of integrated peak areas 
associated with the protonated m/z of the disaccharide units. Standard error was 
calculated for each triplicate set of analyses. IC50 values were calculated using a four 
parameter logistic standard curve analysis function in SigmaPlot (v 13). 
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CHAPTER IV 
 
SECONDARY METABOLITES FROM THE LEAVES 
OF THE MEDICINAL PLANT GOLDENSEAL 
(HYDRASTIS CANADENSIS) 
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Introduction 
The medicinal plant Hydrastis canadensis L. (Ranunculaceae) has a long history 
of use for the treatment of infections. Native Americans, particularly the Cherokee, used 
goldenseal roots to treat skin and eye infections, while other populations have used 
goldenseal tonics to treat gastrointestinal irritation (81). H. canadensis roots have been 
extensively profiled (6, 82, 83), although only a few reports have described the 
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composition of H. canadensis leaves (9, 84). H. canadensis has been of recent interest 
due to its ability to inhibit the growth of pathogenic bacteria, including Staphylococcus 
aureus (72). This activity was originally attributed to the antimicrobial alkaloid berberine 
and to other alkaloids that the plant contains (85-87). Recently, it has been shown that the 
activity of H. canadensis leaves is more complex. Three flavonoids, sideroxylin, 6-
desmethyl sideroxylin and 8-desmethyl sideroxylin (9) were shown to synergistically 
enhance the antimicrobial activity of goldenseal alkaloids. These flavonoids act as 
bacterial efflux pump inhibitors, facilitating accumulation of berberine within bacterial 
cells and thereby reducing the necessary quantity of berberine (or other alkaloids) to 
achieve antimicrobial activity (9). 
Botanicals are chemically complex and contain many compounds that may 
possess diverse structures and biological activities. On the basis of the previously 
reported interesting biological activity of H. canadensis leaves, we endeavored to 
conduct more in-depth chemical profiling of this botanical. With these studies, we sought 
to identify efflux pump inhibitors from H. canadensis, and to generate a more 
comprehensive profile of chemical compounds in this botanical than has previously been 
published.  
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Results and Discussion 
Structures of isolated compounds 
 
 
 
Figure 12. Structures of Compounds, Some of Which Are Reported For The First Time In This 
Report As Constituents of Goldenseal (Hydrastis canadensis). The configuration at locations with 
asterisks are unknown. 
 
 
Investigation of Hydrastis canadensis leaves led to isolation of two new 
compounds, 3,4-dimethoxy-2-(methoxycarbonyl)benzoic acid (10) and 3,5,3´-trihydroxy-
7,4´-dimethoxy-6,8-C-dimethyl-flavone (11), together with six additional compounds 
(12-17) that are known but new to Hydrastis canadensis (Figure 12). (±)-Chilenine (12), 
an isoindolobenzazepine alkaloid, was previously reported from Berberis enpetrifolia 
(88); flavonones (2R)-5,4´-dihydroxy-6-C-methyl-7-methoxy-flavanone (13) and 5,4´-
dihydroxy-6,8-di-C-methyl-7-methoxy-flavanone (14) were isolated from leaf wax of 
Callistemon coccineus (89); and the isoquinolone derivatives noroxyhydrastinine (15) 
and oxyhydrastinine (16) were obtained from Thalictrum minus and Hypecoum erectum, 
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respectively (90, 91). Compound 17, 4´,5´-dimethoxy-4-methyl-3´-oxo-(1,2,5,6-
tetrahydro-4H-1,3-dioxolo-[4´,5´:4,5]-benzo[1,2-e]-1,2-oxazocin)-2-spiro-1´-phtalan, 
was reported previously as a product of ß-hydrastine-N-oxide under reflux conditions 
(92). Given that ß-hydrastine is an abundant constituent of H. canadensis (83), it is 
possible that compound 17 is an isolation artifact and not a constituent of H. canadensis. 
Additionally, nine compounds known to be constituents of H. canadensis were also 
isolated. These include berberine (18) (93), (-)-canadine (19) (94), sideroxylin (20), 6-
desmethyl-sideroxylin (21), 8-desmethyl-sideroxylin (22) (9), ß-hydrastine (23) (95), (-)-
8-oxocanadine (24), 8-oxotetrahydrothalifendine (25) (96), and oxyberberine (26) (97). 
The structures of these known compounds were determined by comparing their 
spectroscopic data with those reported in the literature. 
Compound 10 was obtained as white amorphous powder. High resolving power 
electrospray ionization mass spectrometry (HRESIMS) analysis indicated an ion peak at 
m/z 241.0702 [M+H]
+
 (calcd for C11H13O6
+
, 241.0707), suggesting six degrees of 
unsaturation. The NMR spectral data (Table 3) allowed the assignment of two aromatic 
protons (δH = 6.98 and 7.87) and three methoxy groups (δH = 3.87, 3.94 and 3.95). The 
HMBC analysis allowed correlation of two of the methoxy groups, (δH = 3.87 and 3.95) 
with carbon C-3 and C-4 (δC = 145.9 and 157.4), respectively. Additionally, the 
correlation between H-5 (δH = 6.98) and the resonance at δC = 145.9 (C-3), and between 
H-6 (δH = 7.87) with δC = 157.4 (C-4) supported the placement of the methoxy groups. 
The HMBC correlations between H-5 (δH = 6.98) and δC = 118.7, and H-6 (δH = 7.87) 
with δC = 131.8 supported the assignment of the carboxylic group at C-1 and the 
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methoxycarbonyl group at C-2 (Figure 13). Therefore, the structure of 1 was established 
as 3,4-dimethoxy-2-(methoxycarbonyl)benzoic acid. 
 
 
 
Figure 13. HMBC Correlations of 10. 
 
 
Compound 11, obtained as a yellow amorphous powder, showed in HRESIMS an 
ion peak at m/z 359.1129 [M+H]
+
 (calcd for C19H19O7, 359.1125). The UV maxima 
absorption bands at λmax 377, 346 and 258 nm were suggestive of a flavone skeleton, 
given that the absorbance maxima of flavonols are generally at longer wavelengths (350 
–385 nm) (98). The 
1
H-NMR data (Table 4) indicated the presence of two aromatic 
methoxy groups (δH = 3.80 and 4.00), two C-methyls (δH = 2.41 and 2.23), and three 
aromatic protons (δH = 7.87, 7.82 and 7.00). Analysis of the 
13
C-NMR spectrum (Table 4) 
showed the presence of a α,β-unsaturated carbonyl (δC = 175.9) and a signal at δC = 
136.2, which together with the proton signals of the aromatic rings corresponding to a 
flavonol skeleton. HMBC correlations of 7-OCH3 (δH = 3.80), 6-CH3 (δH = 2.23) and 8-
CH3 (δH = 2.41) methyl protons with C-7 (δC = 163.0) support the position of the 
substituents in ring A (Figure 14). In addition, the methoxy and hydroxy group in the B 
ring were assigned based on the correlation between 4´-OCH3 (δH = 4.00) with the C-4´ 
(δC = 148.4), and the correlations between 5´-H (δH = 7.00) with C-1´ (δC = 124.6) and C-
3´ (δC = 145.8) in the HMBC spectrum. Additionally, the HMBC correlations between 
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2´-H (δC = 7.82) and 6´-H (δH = 7.87) with C-2 (δC = 145.8) supported the connectivity of 
ring B to C-2 (ring C) (Figure S11). On the basis of this evidence, the compound was 
determined to be 3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-C-dimethyl-flavone. 
 
 
 
Figure 14. HMBC Correlations of 11. 
 
 
Table 3. 
1
H (400 MHz) and 
13
C (100 MHz) NMR Spectroscopic Data
a
 for 3,4-dimethoxy-
2-(methoxycarbonyl)benzoic acid (10). 
 
Position  δC  δH, m (J in Hz) 
1  118.7   
2  131.8   
3  145.9   
4  157.4   
5  112.2  6.98, d (8.8) 
6  128.4  7.87, d (8.8) 
1a  168.6   
2a  167.5   
3-OCH3  61.9  3.87, s 
4-OCH3  56.3  3.95, s 
2a-OCH3  53.0  3.94, s 
a 1H and 13C chemical shifts with reference to CDCl3 (δH = 7.26 ppm) and CDCl3 (δC = 77.16 
ppm), respectively. 
b HMBC correlations are from the proton stated to the indicated carbon. 
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Table 4. 
1
H (400 MHz) and 
13
C (100 MHz) NMR Spectroscopic Data
a
 for 3,5,3´-
trihydroxy-7,4´-dimethoxy-6,8-C-dimethyl-flavone (2). 
 
Position  δC  δH, m (J in Hz)  HMBC
b
 
2  146.8     
3  133.9     
4  174.3     
5  155.9     
6  113.4     
7  163.9c     
8  109.7     
9  151.6     
10  106.8     
1´  124.5     
2´  113.7  7.82, d (2.4)   
3´  145.7     
4´  148.4     
5´  110.6  7.00, d (8.4)  C-1´, C-3´ 
6´  121.1  7.88, dd (8.4, 2.4)  C-2´ 
6-CH3  8.4  2.21, s  C-5, C-6, C-7 
8-CH3  8.7  2.39, s  C-7, C-8, C-9 
7-OCH3  60.8  3.79, s  C-7 
4´-OCH3  56.2  3.98, s  C-4´ 
3-OH    11.81   
3´-OH    5.73   
5-OH    6.66   
a 1H and 13C chemical shifts with reference to CDCl3 (δH = 7.26 ppm) and CDCl3 (δC = 77.16 
ppm), respectively. 
b HMBC correlations are from the proton stated to the indicated carbon. 
c obtained from HMBC 
 
Reisolation of known compounds from botanical extracts is a common problem 
when seeking to identify novel compounds from botanicals such as H. canadensis. To 
facilitate future identification of compounds 10−26 in botanical mixtures, tandem high 
resolving power electrospray ionization mass spectrometry (HRESIMS-MS) was 
employed to collect fragmentation spectra of all seventeen compounds in both the 
positive ion mode (Table S1) and the negative ion mode (Table S2). Notably, these 
fragmentation spectra were collected with high mass accuracy (<10 ppm), enabling the 
confirmation of molecular formulae of many of the fragments. An example of such a high 
resolution fragmentation spectrum is provided in  Figure 4 for 11. A fragmentation 
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spectrum of berberine (18), the most abundant alkaloid present in goldenseal (83) can be 
found as Supporting Information (Figure S27). High mass accuracy measurements of 
fragmentation data enable assignment of molecular formulae not just for the intact 
molecule, but also for its fragments (Figure 15). These data were uploaded into the 
Global Natural Product Social molecular networking library to facilitate identification of 
these compounds as well as structural analogues in other botanicals (28). 
 
 
 
Figure 15. Accurate Mass Fragmentation Spectrum of 3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-C-
dimethyl-flavone (11) In The Positive Polarity. Fragments and molecular formulas were predicted using 
ACD MS fragmenter (Advanced Chemistry Development, Inc. Toronto, Canada) and compared to 
experimental data. Bold ions had a mass error within 10 ppm of the associated molecular formula. 
 
Efflux pump inhibitory activity of isolated compounds 
The two new compounds isolated as part of this study [3,4-dimethoxy-2-
(methoxycarbonyl)benzoic acid (10) and 3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-C-
dimethyl-flavone (11)], as well as the compounds 13 and 25 were tested for biological 
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activity. Specifically, a mass spectrometry based assay was employed to evaluate the 
ability of these compounds to inhibit efflux of an efflux pump substrate (ethidium 
bromide) from Staphylococcus aureus cells (30). The rationale for evaluating efflux 
pump inhibitory activity is that drug efflux constitutes a major form of antibiotic 
resistance in bacteria (99). Thus, compounds that prevent efflux of toxins from cells have 
the potential of contributing to antimicrobial activity. Efflux inhibitory activity against 
Staphylococcus aureus is particularly relevant given that this pathogen is responsible for 
approximately 50% of all skin infections, and Hydrastis canadensis is traditionally used 
in the treatment of such infections (100).  
Compound 2 demonstrated moderate inhibitory activity of efflux from 
Staphylococcus aureus with an IC50 value of 180  6 M. Compounds 10, 13 and 25 
were inactive.  Figure 16 shows the raw experimental data evaluating the efflux pump 
inhibitory activities of compounds 10, 11, and the positive control, carbonyl cyanide m-
chloro phenylhydrazone (CCCP), which had an IC50 of 270  50 M. The data shown are 
relative quantities (as measured by mass spectrometric peak area) of ethidium ion in the 
spent bacterial media after exposure to an increasing amount of the test compound or 
control. As demonstrated for both CCCP and 11, when efflux is blocked, the quantity of 
ethidium present in the media decreases (Figure 16). Ethidium concentration remains 
high regardless of concentration for the compound that does not possess efflux inhibitory 
activity (Compounds 10, 13 & 25). 
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Figure 16. Efflux Pump Inhibition Assay Data for 3,4-dimethoxy-2-(methoxycarbonyl) benzoic acid 
(10) and 3,5,30 -trihydroxy-7,40 -dimethoxy-6,8-C-dimethyl-flavone (11). The positive control for this 
assay is carbonyl cyanide m-chloro-phenylhydrazone (CCCP), a compound that inhibits efflux by 
collapsing the proton motive force across the cell membrane (101). Each data point is the mean of triplicate 
measurements from separate bacterial cultures (biological replicates) and error bars represent standard error 
of the mean. 
 
 
Experimental 
General experimental procedures 
Optical rotations at the sodium D-line wavelength of pure compounds were 
measured with a Rudolph Research Autopol (II) Polarimeter. 1D and 2D NMR spectra 
were recorded using a JEOL ECS-400 NMR spectrometer equipped with a high 
sensitivity JEOL Royal probe operating at 400 MHz for 
1
H and 100 MHz for 
13
C, or an 
Agilent 700 MHz NMR spectrometer (Agilent Technologies, Inc., Santa Clara, CA, 
USA) equipped with a cryoprobe, operating at 700 MHz for 
1
H and 175 MHz for 
13
C. 
Chemical shifts are reported as δ values (ppm), and coupling constants (J) were measured 
in Hz. HRESIMS was performed on a Thermo LTQ Orbitrap XL mass spectrometer 
equipped with an electrospray ionization source. HPLC was carried out using a Varian 
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ProStar HPLC system equipped with ProStar 210 pumps and a ProStar 335 photodiode 
array detector (PDA), with data collected and analyzed using Galaxie Chromatography 
Workstation software (version 1.9.3.2). For preparative HPLC, a Phenomenex Gemini-
NX C18 Column (5 µm; 250 × 21.2 mm) was used at a 21 mL/min flow rate. Flash 
chromatography was performed on a Teledyne ISCO CombiFlash
®
Rf using 80 g or 120 g 
RediSep
®
 RF Silica Column (35 ‒ 70 µm particle size) and 12 g RediSep
®
 Rf Gold HP 
Silica Columns (20 ‒ 40 µm particle size, Teledyne ISCO, Lincoln, NE, USA); and 
monitored by UV and evaporative light-scattering detectors. UV spectra were measured 
with a ProStar 335 photodiode array UV detector (PDA) and the reported λmax values 
were collected from the spectra for relevant compounds eluting from the HPLC. All other 
reagents and solvents were obtained from Fisher Scientific and were used without further 
purification. 
Plant material 
Hydrastis canadensis L. (Ranunculaceae) was collected in Hendersonville, North 
Carolina (NC, N 3524.2770, W 08220.9930, 702.4 m elevation), in July 2013. The plants 
were cultivated in their native environment, a hardwood forest understory. A voucher 
specimen (NCU583414) was deposited in the University of North Carolina Herbarium, 
Chapel Hill, NC and the identity was verified by herbarium director Dr. Alan S. Weakley. 
Extraction and isolation 
The isolation scheme is provided as Supporting Information (Figure S2). Batches 
of dried H. canadensis plant were pulverized into fine powder using a commercial coffee 
grinder (Kitchen Aid). H. canadensis powder was percolated in MeOH overnight, and the 
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MeOH extract was concentrated in vacuo and subjected to liquid-liquid partition, as 
described previously (9). This concentrated extract was defatted by partitioning between 
10% aqueous MeOH and hexane (1:1), and the aqueous MeOH fraction was partitioned 
further between EtOAc:MeOH:H2O (4:1:5). The organic layer was washed with 1% 
saline solution to remove tannins. 
The first stage of normal-phase flash chromatography (120 g silica gel column) 
was conducted with a Hex/CHCl3/MeOH gradient, yielding 8 primary fractions (FI-
FVIII). Fraction FII, FIII and FIV were subjected to a second stage of normal-phase flash 
chromatography (80 g silica gel column) with a Hex/EtOAc/MeOH gradient to give 5 
(FII1-FII5), 3 (FIII1-FIII3) and 6 (FIV1-FIV6) subfractions, respectively. 
The compounds were purified using reversed-phase preparative HPLC with a 
Phenomenex Gemini-NX C18 column at a 21 mL/min flow rate. Fraction FII2 (32.5 mg) 
(eluents A: H2O 0.1% formic acid, B: CH3CN, gradient: B 45% at time 0, B 75% at time 
20 min, B 100% at time 25 min) yielded the compounds (2R)-5,4´-dihydroxy-6-C-
methyl-7-methoxy-flavanone (13; 1.5 mg), 5,4´-dihydroxy-6,8-di-C-methyl-7-methoxy-
flavanone (14; 0.7 mg), and 3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-C-dimethyl-flavone 
(11; 0.6 mg). 
Fractions FII3 (30.1 mg), FII4 (7.3 mg) and FIII1 (26.9 mg) were purified 
(eluents A: H2O 0.1% formic acid, B: CH3CN, gradient: B 35% at time 0, B 90% at time 
27 min, B 100% at time 30 min) to obtain oxyhydrastinine (16; 2.0 mg), chilenine (12; 
0.8 mg) for the first fraction, noroxyhydrastinine (15; 0.9 mg) for the second fraction, and 
(2R)-5,4´-dihydroxy-6-C-methyl-7-methoxy-flavanone (13; 0.5 mg) for the last fraction. 
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Fraction FIV3 (96.3 mg) (eluents A: H2O 0.1% formic acid, B: CH3CN, gradient: 
B 30% at time 0, B 90% at time 20 min, B 100% at time 22 min) and fraction FIV5 (42.3 
mg) (eluents A: H2O 0.1% formic acid, B: CH3CN, gradient: B 30% at time 0, B 65% at 
time 20 min, B 100% at time 22 min) yielded chilenine (12; 1.0 mg) and 3,4-dimethoxy-
2-(methoxycarbonyl) benzoic acid (10; 1.2 mg), respectively. 
3,4-dimethoxy-2-(methoxycarbonyl)benzoic acid (10): white powder; UV λmax 208 
and 259 nm; 
1
H (400 MHz) and 
13
C NMR (100 MHz) data see Table 1. HRESIMS m/z 
241.07021 [M+H]
+
 (calcd for C11H13O6 241.0707). 
3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-C-dimethyl-flavone (11): yellow powder; 
UV λmax 217, 258, 346 and 377 nm; 
1
H (700 MHz) and 
13
C NMR (175 MHz) data see 
Table 2. HRESIMS m/z 359.11287 [M+H]
+
 (calcd for C19H19O7 359.1125). 
(±)-chilenine (12): white powder; [𝛼]D
25 = 0.0 (c 0.22, MeOH); UV λmax 215 and 
318 nm; 
1
H-NMR (400 MHz, CDCl3) δ: 7.36 (1H, d, J = 8.4 Hz, H-11), 7.05 (1H, d, J = 
8.4 Hz, H-12), 6.71 (1H, s, H-1), 6.66 (1H, s, H-4), 5.95 (2H, dd, J = 7.2, 1.2 Hz, 
OCH2O), 4.26 (1H, m, H-6), 3.99 (3H, s, OCH3-9), 3.87 (3H, s, OCH3-10), 3.56 (1H, m, 
H-5), 3.30 (1H, m, H-6), 3.11 (1H, m, H-5); 
13
C-NMR (100 MHz, CDCl3) δ: 199.8 (C-
14), 166.7 (C-8), 154.5 (C-10), 151.6 (C-3), 147.1 (C-2), 146.7 (C-9), 133.7 (C-4a), 
131.7 (C-12a), 130.7 (C-14a), 124.1 (C-9a), 120.6 (C-12), 116.3 (C-11), 109.4 (C-4), 
109.2 (C-1), 101.9 (OCH2O), 94.9 (C-13), 62.6 (OCH3-9), 56.6 (OCH3-10), 38.9 (C-6), 
30.7 (C-5); HRESIMS m/z 384.10751 [M+H]
+
 (calcd for C20H18NO7 384.1078). 
(2R)-5,4´-dihydroxy-6-C-methyl-7-methoxy-flavanone (13): yellow oil; [𝛼]D
25 = -
7.33 (c 0.3, MeOH); UV λmax 216, 291 and 338 nm; 
1
H-NMR (400 MHz, CDCl3) δ: 12.1 
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(OH-5), 7.35 (2H, d, J = 8.4 Hz, H-2´ and H-6´), 6.89 (1H, d, J = 8.4 Hz, H-3´ and H-5´), 
6.07 (1H, s, H-8), 5.35 (1H, dd, J = 13.2, 2.8, H-2), 3.83 (3H, s, OCH3-7), 3.09 (1H, dd, J 
= 17.2, 13.2 Hz, H-3), 2.77 (1H, dd, J = 17.2, 2.8 Hz, H-3), 2.01 (1H, s, CH3-6); 
13
C-
NMR (100 MHz, CDCl3) δ: 196.2 (C-4), 165.8 (C-7), 161.3 (C-9), 160.5 (C-5), 156.2 (C-
4´), 130.9 (C-1´), 128.1 (C-2´ and C-6´), 115.8 (C-3´ and C-5´), 106.1 (C-6), 102.9 (C-
10), 90.9 (C-8), 79.2 (C-2), 55.9 (OCH3-7), 43.5 (C-3), 7.0 (CH3-6); HRESIMS m/z 
301.10709 [M+H]
+
 (calcd for C17H17O5 301.10780). 
5,4´-dihydroxy-6,8-di-C-methyl-7-methoxy-flavanone (14): yellow oil; [𝛼]D
25 = -
6.86 (c 0.12, MeOH); UV λmax 192, 222, 282 and 361 nm; 
1
H-NMR (400 MHz, CDCl3) 
δ: 12.0 (OH-5), 7.35 (2H, d, J = 8.4 Hz, H-2´ and H-6´), 6.89 (1H, d, J = 8.4 Hz, H-3´ 
and H-5´), 5.34 (1H, dd, J = 12.8, 2.8 Hz, H-2), 3.74 (3H, s, OCH3-7), 3.06 (1H, dd, J = 
17.2, 12.8 Hz, H-3), 2.83 (1H, dd, J = 17.2, 2.8 Hz, H-3), 2.10 (3H, s, CH3-6), 2.07 (3H, 
s, CH3-8); 
13
C-NMR (100 MHz, CDCl3) δ: 197.7 (C-4), 162.5 (C-7), 160.2 (C-5), 158.1 
(C-4´), 156.4 (C-9), 131.5 (C-1´), 127.8 (C-2´ and C-6´), 119.5 (C-8),116.2 (C-3´ and C-
5´), 108.2 (C-6), 104.0 (C-10), 79.7 (C-2), 63.5 (OCH3-7), 40.7 (C-3), 9.9 (CH3-8), 9.3 
(CH3-6); HRESIMS m/z 315.12292 [M+H]
+
 (calcd for C18H19O5 315.1227). 
Noroxyhydrastinine (15): yellow powder; UV λmax 222, 261 and 306 nm; 
1
H-
NMR (400 MHz, CDCl3) δ: 7.50 (1H, s, H-8), 6.66 (1H, s, H-5), 6.01 (2H, s, OCH2O), 
3.53 (2H, t, J = 6.8, 6.4 Hz, H-3), 2.91 (1H, t, J = 6.8, 6.4 Hz, H-4); 
13
C-NMR (100 MHz, 
CDCl3) δ: 166.5 (C-1), 151.5 (C-6), 147.2 (C-7), 135.0 (C-5a), 121.5 (C-8a), 108.0 (C-8), 
107.5 (C-5), 101.8 (OCH2O), 40.4 (C-3), 28.3 (C-4); HRESIMS m/z 192.06526 [M+H]
+
 
(calcd for C10H10NO3 192.0655). 
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Oxyhydrastinine (16): yellow pale powder; UV λmax 222, 264 and 304 nm; 
1
H-
NMR (400 MHz, CDCl3) δ: 7.54 (1H, s, H-8), 6.61 (1H, s, H-5), 5.99 (2H, s, OCH2O), 
3.51 (2H, t, J = 6.8, 6.8 Hz, H-3), 2.90 (1H, t, J = 6.8, 6.8 Hz, H-4), 3.13 (3H, s, N-CH3); 
13
C-NMR (100 MHz, CDCl3) δ: 164.7 (C-1), 150.4 (C-6), 146.9 (C-7), 133.6 (C-5a), 
123.5 (C-8a), 108.3 (C-8), 107.0 (C-5), 101.6 (OCH2O), 48.3 (C-3), 35.3 (N-CH3), 28.1 
(C-4); HRESIMS m/z 206.08127 [M+H]
+
 (calcd for C11H12NO3 206.08117). 
4´,5´-dimethoxy-4-methyl-3´-oxo-(1,2,5,6-tetrahydro-4H-1,3-dioxolo-[4´,5´:4,5]-
benzo[1,2-e]-1,2-oxazocin)-2-spiro-1´-phtalan (17): yellow pale powder; [𝛼]D
25 = + 4.8 (c 
0.17, MeOH); UV λmax 218, 245 and 300 nm; 
1
H-NMR (400 MHz, CDCl3) δ: 7.04 (2H, 
d, J = 8.4 Hz, H-6´), 6.75 (1H, s, H-7), 6.36 (1H, s, H-11), 6.33 (1H, d, J = 8.4 Hz, H-7´), 
6.00 and 5.94 (2H, s, OCH2O), 4.28 (1H, m, H-1), 4.11 (3H, s, OCH3-4´), 3.88 (3H, s, 
OCH3-5´), 3.35 (1H, m, H-6), 3.07 (2H, m, H-5), 2.76 (3H, s, N-CH3), 2.70 (2H, m, H-1 
and H-6); 
13
C-NMR (100 MHz, CDCl3) δ: 165.8 (C-3´), 154.0 (C-5´), 148.1 (C-4´), 146.9 
(C-8), 145.4 (C-10), 138.9 (C-7´a), 135.1 (C-7a), 126.9 (C-11a), 119.7 (C-7´), 119.1 (C-
4´a), 118.0 (C-6´), 112.6 (C-11), 111.1 (C-7), 109.5 (C-2), 101.2 (C-9), 62.5 (OCH3-4´), 
62.1 (C-5), 56.8 (OCH3-5´), 49.2 (N-CH3), 40.6 (C-1), 36.6 (C-6); HRESIMS m/z 
400.1375 [M+H]
+
 (calcd for C21H22NO7 400.1391). 
Collection of HRESIMS fragmentation data 
Each of the 17 isolated compounds were suspended in MeOH at either 1 mg/mL 
or 0.1mg/mL and subjected to ultraperformance liquid chromatography tandem mass 
spectrometry (UPLC-MS/MS) analysis via a Waters Acquity UPLC with an Acquity 
UPLC column (BEH C18, 1.7 μm, 2.1 x 50 mm), Waters Corporation, Milford, MA) 
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coupled to a Thermo Q Exactive Plus orbitrap mass spectrometer with heated 
electrospray ionization (Thermo Fisher Scientific, MA, USA). The compounds were 
eluted from the column at a flow rate of 0.3 mL/min using a binary solvent system with A 
consisting of water with 0.1% formic acid additive and solvent B consisting of 
acetonitrile with 0.1% formic acid additive. The gradient was as follows: 95:5 (A:B) from 
0 to 1 min, increasing to 90:10 (A:B) from 1 to 2 min, 80:20 (A:B) from 2 to 3 min, 
60:40 (A:B) from 3 to 4 min, 70:30 (A:B) from 4 to 5 min, 0:100 (A:B) from 5 to 6 min 
and held from 6 to 7 min, 95:5 (A:B) from 7 to 8 min and held from 8 to 9 min. Duplicate 
analyses of each sample were conducted in both positive and negative polarities using the 
following settings: spray voltage, 3.7 kV; capillary temperature, 350 °C; sheath gas, 25; 
auxiliary gas, 5; S-lens RF level, 50. Each compound was chosen for fragmentation via 
high energy collision-induced dissociation (HCD, normalized collision energy set to 50) 
from an inclusion list for both polarities. To determine the average mass accuracy of the 
product ions, the fragmentation spectra of 11 was compared to theoretical fragments 
produced by ACD MS fragmenter (Advanced Chemistry Development, Inc. Toronto, 
Canada). The resulting accurate mass of the predicted chemical formulas were matched 
with experimental data and were within 10 ppm mass error (Figure 15). 
Efflux pump inhibition assay 
Four of the isolated compounds (10, 11, 13 and 25) were of sufficient purity 
(91%, 98%, 95% and 100%, respectively, by LC-UV) and quantity for evaluation via an 
efflux pump inhibition assay, as previously described (30). The assay was modified from 
the previously reported method in the chromatographic gradient, in some of the mass 
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spectrometric conditions, and in the use Staphyloccocus aureus strain SA1199 (102). 
The gradient was as follows: 95:5 (A:B) from 0 to 1 min, increasing to 0:100 (A:B) from 
1 to 3.5 min, held from 3.5 to 9.5 min, 95:5 (A:B) from 9.5 to 10 min. A divert valve was 
utilized, with the valve set to waste from 0 to 1.5 min and to inject from 1.5 to 10 min. 
The mass spectrometric analyses were conducted under the following conditions: spray 
voltage, 3 kV; capillary temperature, 250°C; vaporizer temperature, 40°C; sheath gas, 40; 
aux gas, 30; tube lens offset, -112. Mass spectral dose-response data were analyzed with 
SigmaPlot (Systat Software, San Jose, CA) to calculate IC50 values for each of the active 
compounds. 
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CHAPTER V 
BIOCHEMOMETRICS TO IDENTIFY SYNERGISTS AND ADDITIVES 
FROM BOTANICAL MEDICINES: A CASE STUDY WITH 
HYDRASTIS CANADENSIS (GOLDENSEAL) 
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Introduction 
In traditional and modern alternative health care practices, botanical extracts are 
employed frequently for medicinal purposes as complex mixtures. The claim is often 
made that such mixtures are more effective than their constituents in isolation due to 
additive or synergistic interactions among compounds (103-106). However, the 
identification of the chemical constituents responsible for the observed activity of 
complex extracts remains a challenging pursuit.  
The traditional approach to identify active compounds from botanical mixtures, 
bioassay-guided fractionation, is highly effective for studying natural product mixtures 
when the activity can be traced to single, highly potent active compounds. Unfortunately, 
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it is more difficult to effectively employ bioassay-guided fractionation when the activity 
of the mixture results from multiple compounds with low potency. Recently, a 
modification of the bioassay-guided fractionation approach designed to aid in the 
identification of multiple active compounds in a mixture, “synergy-directed 
fractionation” was developed (9). With synergy-directed fractionation, a botanical extract 
is fractionated and the resulting fractions are tested for activity in combination with a 
known active constituent of the original extract. This approach was shown to be effective 
for identifying synergists in [Hydrastis canadensis L. (Ranunculaceae)] (9). However, 
one of the limitations of synergy-directed fractionation is that this technique, like 
bioassay-guided fractionation, is inherently biased towards the compounds that are most 
easily isolated. Even though the methodology focuses on the most active fractions for 
isolation efforts, these fractions are often so complex that it is not possible to isolate 
every compound that they contain. Characteristics such as the abundance of a given 
compound and/or its ease of separation typically guide the isolation process in the latter 
steps, rather than true biological activity. As a result, the “active” compounds identified 
may represent only a subset of those responsible for the activity of the original mixture.  
There has recently been a great deal of interest among the scientific community in 
the application of untargeted metabolomics to identify active mixture compounds (35-40, 
107). With this approach, analytical methods (typically NMR or MS) are employed to 
detect as many of the small molecules in a mixture as possible (the “metabolome”), 
without bias towards which are chemically or biologically interesting. For metabolomics 
data to be employed for identification of active mixture components, it is necessary to 
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collect metabolite profiles and corresponding biological assay data for a series of 
mixtures. Statistical methods are then employed to correlate chemical profile to 
bioactivity, a process which has been termed “biochemometrics” (108).  
In theory, biochemometrics has the potential to overcome some of the 
aforementioned limitations of bioassay-guided fractionation, and to provide a more 
comprehensive representation of which compounds are responsible for the activity of a 
botanical extract. However, the inherent complexity of botanical extracts makes the data 
analysis aspects of the biochemometrics challenging when employed for this purpose. 
Several data analysis approaches have been employed to address this challenge. Inui et al. 
applied Pearson correlation coefficients to 2D orthogonal chromatography and 
incorporated biological data to identify mass spectral ions for which variance positively 
correlated with biological activity (39). Pearson correlation coefficients are a univariate 
statistical approach to measure the strength of linear correlation between single pairs of 
variables (i.e., concentration and biological activity) in isolation. A limitation of this 
approach is that the Pearson correlation does not consider potential interactions between 
variables, and is easily skewed by such outliers (109). In contrast, Kulakowski et al. 
utilized unsupervised principal component analysis (PCA) and supervised orthogonal 
partial least-squares discriminatory analysis (OPLS-DA) to correlate bioactivity to LC-
MS profiles (37). PCA can used to group samples based upon covariance, so fractions 
with similar profiles will be clustered while others will be in a different location in the 
PCA score plot. PCA is useful for describing chemical differences among samples, but 
does not provide insight into which of the constituents of these samples are biologically 
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active. OPLS-DA allows for the incorporation of biological data, which were in this case 
binary classifications, i.e., active/nonactive fractions (37). OPLS-DA plots appear similar 
to PCA plots, and an OPLS-DA model can represented as an S-plot, where each axis 
represents the covariance and correlation loading variables (110). Biomarkers with 
intensities that correlate and co-vary with the bioactivity appear the furthest from the 
origin (36, 37). An important limitation of this approach is that co-variance increases 
with increased concentration of a constituent, such that the approach is biased towards 
selection of abundant constituents at the expense of low-abundant compounds that may 
have high biological activity (35).  
Selectivity ratio plots are derived from the ratio of explained and residual variance 
on a single univariate component that incorporates bioactivity information in the 
multivariate PLS model, and can thus be employed to identify mixture components that 
are most strongly associated with an observed biological effect independent of 
concentration (35). Selectivity ratios were first applied to identifying biomarkers of 
diseases from complex cerebrospinal fluid data sets (34). Recently, the applicability of 
this biochemometrics approach using selectivity ratios to identify biologically active 
compounds from fungal extracts was demonstrated (35). As of yet, this approach has not, 
however, been applied to botanical extracts. Compared to botanicals, fungi produce 
relatively simple mixtures of chemical compounds. Thus, it is expected that the 
application of this biochemometric approach to botanical extracts, which are more 
complex, would be more challenging. Furthermore, an added challenge with botanical 
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extracts is that their greater complexity means that synergistic, additive, or antagonistic 
interactions are likely to occur (111).  
With the study presented herein, an approach combining biochemometrics with 
synergy-directed fractionation to identify active compounds and/or synergists from a 
botanical extract was developed. As a case study, the botanical Hydrastis canadensis was 
selected, which is used widely in alternative healthcare practices for the treatment of 
infections (10, 112). Activity against the common Gram-positive bacterium 
Staphylococcus aureus was evaluated, given that H. canadensis has previously been 
shown to possess activity against this pathogen (72).(113)(113) 
Earlier studies with H. canadensis have identified several compounds that interact 
synergistically to effect antimicrobial activity; thus, this botanical serves as a useful test 
case for evaluating a new approach to identify synergists. Specifically, H. canadensis is 
known to contain a number of flavonoids (sideroxylin, 6-desmethyl-sideroxylin, 8-
desmethyl-sideroxylin, 3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-di-C-dimethylflavone, 5,4´-
dihydroxy-6-C-methyl-7-methoxyflavone, 5,4´-dihydroxy-6,8-di-C-methyl-7-
methoxyflavone, 6,8-di-C-methylluteolin-7-methyl ether, and 6-C-methylluteolin-7-
methyl ether [20-22, 11, 13, 14, 27, 28, respectively]), alkaloids, and other compounds 
(berberine, oxyberberine, berberastine, tetrahydroberberastine, canadine, canadaline, 
canadinic acid, 8-oxocanadine, β-hydrastine, hydrastidine, hydrastinine, oxyhydrastinine, 
noroxyhydrastinine, chilenine, 4´,5´-dimethoxy-4-methyl-3´-oxo(1,2,5,6-tetrahydro-4H-
1,3-dioxolo-[4´,5´:4,5]-benzo[1,2-e]-1,2-oxazocin)-2-spiro-1´-phtalan, 8-
oxotetrahydrothalifendine, corypalmine, isocorypalmine, tetrahydropalmatine, and 3,4-
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dimethoxycarbonylbenzoic acid [18, 29, 30, 19, 31, 32, 24, 23, 33, 34, 16, 15, 12, 17, 25, 
35-37, 10]) with diverse structures (87, 114). Recently, it was shown that the flavonoids 
from H. canadensis sideroxylin (20), 6-desmethyl-sideroxylin (21), and 8-desmethyl-
sideroxylin (22) enhance synergistically the antimicrobial activity of the alkaloid 
berberine (18) against S. aureus by acting as bacterial efflux pump inhibitors (9). In a 
separate report, the flavonoid 3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-C-dimethylflavone 
(11) was also shown to act as an efflux pump inhibitor (114). H. canadensis also contains 
several alkaloids that do not act as efflux pump inhibitors (19, 23, 25) or possess 
biologically relevant antimicrobial activity (26, 19, 31, 32, 23, 25, 35) (11, 86, 87, 96, 
114-119). Finally, a number of compounds have also been identified from H. canadensis 
for which biological activity has not been evaluated (14, 29, 30, 24, 33, 34, 17, 37) (6, 88, 
89, 96, 114, 120-122). Relying on existing knowledge about the chemistry and biological 
activity of H. canadensis, the goal with this investigation was to apply synergy-directed 
fractionation combined with biochemometric data analysis to a H. canadensis extract. 
The ultimate objective of these studies was to evaluate the effectiveness of this 
methodology to identify known active constituents and/or identify new bioactive 
compounds from a botanical extract. 
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Figure 17. Constituents of Hydrastis canadensis. The configuration at locations with asterisks are 
unknown. 
 
Results and Discussion 
For this study, a leaf extract was chosen for evaluation because H. canadensis 
leaves have a higher flavonoid content than the roots. Leaf material also tends to be 
highly complex, therefore, it was anticipated that reducing the complexity by 
fractionating a H. canadensis extract would be necessary to provide useful data for 
biochemometrics analysis. To determine how much fractionation would be necessary, the 
results of biochemometric analysis were compared on a sequential series of H. 
canadensis extract fractions and subfractions with decreasing complexity. Specifically, 
the original extract was subjected to liquid-liquid partitioning initially and then separated 
chromatographically in a series of four stages (Figure S1, Supporting Information). The 
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most active fraction from each stage was moved forward for further separation. To 
evaluate biological activity of the fractions produced by each stage of separation, S. 
aureus cultures were treated with varying concentrations of the alkaloid berberine (a 
known antimicrobial constituent of H. canadensis) in combination with constant 
concentrations of the H. canadensis fractions. The minimum concentration of berberine 
necessary to completely inhibit bacterial growth [minimum inhibitory concentration 
(MIC)] was compared in the presence of each H. canadensis fraction. With this approach, 
fractions containing compounds that enhance the antimicrobial activity of berberine 
(synergistically or additively) will lower the effective MIC of berberine against S. aureus 
(Figure 18). Metabolite profiles of the fractions from each stage of separation were 
collected using high resolving power mass spectrometry (Figure 19), as described in the 
Experimental Section, and biochemometric analyses (using selectivity ratio plots) were 
employed to integrate the metabolite profile data with the results of the bioassay data 
(Figure 20).  
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Figure 18. Minimum Inhibitory Concentration (MIC) of Each Fraction + Berberine Against 
Staphylococcus aureus. Berberine was tested alone, and berberine + piperine served as the positive control. 
Each fraction was combined at a constant concentration of fraction (75 μg/mL) with varying concentrations 
of berberine. See Figure S2 (Supporting Information) for MIC curves. (A) First stage normal phase 
fractions, where GS-4 lowered the MIC the greatest amount. (B) Secondary fractionation of GS-4 via 
normal phase chromatography yielded fractions GS-4-1 through 16, and the fractions therefrom were also 
tested in combination with berberine. (C) This process was repeated for stage 3 which was prepared using 
reversed phase chromatographic separation of GS-4-4. 
 
 
Biochemometrics to guide isolation  
The H. canadensis extract and multiple fractions therefrom demonstrated the 
desired biological effect, an ability to enhance the antimicrobial activity of berberine (i.e., 
reduce its MIC value) against S. aureus (Figure 18; Figure S29). Importantly, the positive 
control, a known efflux pump inhibitor (123) (piperine) also reduced the MIC of 
berberine. From the first stage of fractionation, the strongest activity was observed for 
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fraction 4, which reduced the MIC of berberine from 150 to 18.8 μg/mL (Figure 18A). 
Thus, GS-4 was selected as starting material for subsequent fractionation, yielding a 
series of sub-fractions, from among which fraction GS-4-4 demonstrated the best activity 
(Figure 18B). This process was repeated to produce a subfraction set where GS-4-4-2 
possessed the most potent activity in combination with berberine (Figure 18C) (see 
Figure S28 for fraction labeling scheme). 
A necessary first step in the application of biochemometrics to identify active 
mixture components is that the compounds must be detectable by the analytical approach 
employed (in this case, LC-MS). Thus, the data resulting from LC-MS analysis of the H. 
canadensis extract (Figure 19A and 19F) were inspected to determine whether known H. 
canadensis constituents were detectable. Indeed, a number of flavonoids and alkaloids 
known to be present in H. canadensis were identifiable from the LC-MS data (Figure 19). 
Pursuit of the most biologically active fractions (Figure 18) throughout the isolation 
process resulted in selection of fractions with greater flavonoid abundance with each 
successive stage of isolation (Figure 19). This result is to be expected given that 
flavonoids are known to enhance the antimicrobial activity of alkaloids (106, 124-126), 
and the biological assay used as a basis for this study was enhancement of antimicrobial 
activity of the alkaloid berberine.  
A known limitation of the application of mass spectrometric analysis to evaluate 
chemical composition of mixtures is the selectivity of the technique. Relative abundances 
in LC-MS chromatograms reflect what is most easily ionizable rather than what is truly 
present in the mixture at highest concentration. Inspection of the data resulting from 
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analysis of the H. canadensis extract evaluated herein illustrates this limitation. 
Alkaloids, which are easily protonatable, are highly amenable to analysis with 
electrospray ionization mass spectrometry in the positive-ion mode. Thus, positive-ion 
mode analysis of the H. canadensis resulted in chromatograms dominated by alkaloids 
(Figure 19A-D), at least in the earlier stages of fractionation before these alkaloids were 
separated into inactive fractions. Conversely, data collected in the negative-ion mode 
were dominated by flavonoids, which are more easily deprotonated (Figures 19E-H). It is 
important when conducting metabolomics profiling of a botanical extract to collect data 
in both ionization modes. Additionally, one must always be cognizant of the possibility 
that certain important mixture components may not be detected, and that the relative 
abundances in LC-MS chromatograms may not reflect the actual relative abundances in 
the mixture.  
An advantage of LC-MS is that it enables the simultaneous detection of multiple 
constituents that have the same chromatographic retention time. This phenomenon is 
most apparent from Figure 19A, where eight goldenseal compounds were found within 
one chromatographic peak that eluted around 4.1 minutes. The peak shown represents the 
relative abundance of the most abundant ion during this time span, not the collective 
signal of all ions. For metabolomics analysis, these chromatograms are deconvoluted 
(using MZmine) to identify multiple retention time-mass pairs, even those that co-elute. 
Thus, all detectable ions (above a set noise threshold) are compared with bioactivity and 
correlations are determined, not just those that are apparent in the base peak 
chromatograms. 
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Figure 19. LC-MS Chromatograms (Collected With Ultraperformance Liquid Chromatography 
Coupled to a Q-Exactive Orbitrap Mass Spectrometer) of a Series of H. canadensis Extract 
Fractions. (A) Positive-ion electrospray mass spectrometry chromatogram of the crude extract after liquid-
liquid partitioning. (B) The most active fraction (GS-4) of the crude extract shown in A after separation 
with flash chromatography over silica gel using a hexane/chloroform/methanol gradient (stage 1 
separation). GS-4 was further fractionated using a second stage of flash chromatography over silica gel 
with a hexane/ethyl acetate/methanol gradient with GS-4-4 being the most active (C). GS-4-4-2 generated 
with stage 3 fractionation (using reversed phase preparative HPLC with a water:acetonitrile gradient) (D). 
(E-H) The same H. canadensis extract and fractions analyzed using LC-MS in the negative-ion mode. 
Arrows represent the region of the chromatogram in which a given ion corresponding to a known 
constituent of H. canadensis (indicated by compound numbers) could be detected. Compounds 20-22, 11, 
12, 13, 14, 18, 26, 19, 23, 24, 12, 15-17, 25, and 10 were identified by comparison of retention time and 
fragmentation with authenticated standards (72, 114), while compounds 27-37 were tentatively identified 
by comparison of accurate mass and molecular formula with literature reports (6, 87, 115, 118, 120, 122, 
127). Red dotted arrows represent alkaloids and other compounds, while green dashed arrows represent 
flavonoids. In cases where a specific peak is not apparent in the chromatogram, the ion was identified based 
on mass spectrometric data.  
 
The selectivity ratio plots shown in Figure 20 are the output of biochemometric 
analysis combining the data obtained from biological evaluation (Figure 18) and 
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chemical evaluation (Figure 19) of the H. canadensis extract and fractions. To generate 
these plots, a series of unique marker ions (m/z-retention time pairings) obtained from 
analysis of the LC-MS data were used from each stage of fractionation (595, 612, and 
149 ions for stages one through three, respectively) Previous reports compounded mass 
spectrometric and biological data from previous stages of fractionation to increase 
statistical power.
11
 Due to the chemical complexity of botanical data sets, the selectivity 
ratio plots produced from combining fractionation stages did not result in known 
synergists being predicted as bioactive (data not shown). The selectivity ratio plots 
represent the m/z of each ion detected on the x-axis, and the selectivity ratio (the ratio of 
explained variance to residual variance, which is derived from the PLS model) on the y-
axis for each independent stage of fractionation. Since the biological assay data used for 
this analysis was growth inhibition, the ions with the most negative (pointing down in 
Figure 20) selectivity ratios represent those associated with the desired biological effect 
(antimicrobial activity). Ions with very small selectivity ratios or positive selectivity 
ratios (either no bar or pointing up, respectively, in Figure 20) are not expected to have 
synergistic or additive activity when combined with berberine.  
Selectivity ratio plots (Figure 20) have the advantage over LC-MS or LC-UV 
chromatograms in that the size of bars is representative of constituents possessing the 
desired effect (biological activity) rather than unrelated effects such as high 
concentration, ionizability, or molar absorptivity. Thus, in theory, selectivity ratio plots 
should be extremely helpful for guiding the isolation of bioactive compounds. It is worth 
mentioning here that scientists engaged in bioassay-guided fractionation typically do 
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make decisions about which fractions to pursue for isolation based on which fractions 
possess the greatest biological activity. The challenge, of course, is in deciding which 
components of these fractions to isolate. Typically, a researcher would compare the 
chromatographic profile of active and inactive fractions to determine which peaks differ 
between them. However, when hundreds or thousands of components are present, and 
when more than one fraction is being compared, it becomes very difficult to do this with 
simple visual inspection. Also, visually one tends to be biased by the tallest peaks of 
those most distinctly separated from other peaks (even though these may be neither the 
most abundant nor the most active ions). The use of selectivity ratio plots improves the 
efficiency of the process by comparing all of the detected ions (both active and inactive) 
and corresponding peak areas of all fractions in a given stage of separation with their 
associated biological activity. The result is a quantitative value (the selectivity ratio) that 
describes how well each ion is associated with the observed biological activity 
independent of concentration bias (again, assuming that the ion is detected by the 
analytical method being employed). 
How much fractionation is necessary? 
It is important to recognize an inherent limitation of the biochemometric 
approach, in that associations between activity and chemical composition are correlative, 
rather than causal. It is always possible that ions identified as bioactive in a selectivity 
ratio plot may co-vary in fractions with active ions, but may not possess activity 
themselves. Such ions would represent false positives. The likelihood of observing such 
false positives increases as the chemical complexity of the fractions evaluated increases. 
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Conversely, it is also possible that particular bioactive mixture components might go 
undetected by the analytical approach used, or be at a concentration too low to register a 
biological effect (i.e., antimicrobial activity). Such a scenario would result in a false 
negative. Using H. canadensis as a test case, one of the goals of this study was to 
evaluate empirically the likelihood of occurrence of such false positives and false 
negatives by comparing the results of biochemometric analysis on three different stages 
of fractionation (Figure 20).  
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Figure 20. Selectivity Ratio Plots for First, Second and Third Stages of Fractionation [(A), (B), and 
(C), Respectively] With Green Dashed Arrows Representing Flavonoids and Red Dotted Arrows 
Representing Alkaloids and Other Known Constituents of H. canadensis. The signals of flavonoids and 
the alkaloid berberine, all known to be or predicted to be active in the assay being used, are not prominent 
in first stage fractionation (A) and second stage fractionation (B). (C) Third stage fractionation yielded 
seven flavonoids (20-22, 11, 13, 27, 38) and three alkaloids (26, 12, 17) with negative selectivity ratios 
(suggesting these compounds to contribute additively or synergistically to antimicrobial activity). The bar 
labeled 38* represents the 13C isotope of 38. The identities and activities of compounds represented by 
other prominent peaks are not known.  
 
 
Stage 1 fractions were subjected to subsequent biochemometric analysis, and 
multivariate partial least squares (PLS) modeling of the combined bioassay and spectral 
data matrix yielded the selectivity ratio plot shown in Figure 20A. The selectivity ratio 
plot based on the first stage of separation indicated several false negatives. Although four 
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confirmed active flavonoids (compounds 20-22 and 11) and the alkaloid berberine (18) 
were detected among the ions from this first stage of fractionation (Figure 20A), none of 
these ions was highlighted as major active constituents in the selectivity plot (i.e., ions 
with large negative selectivity ratios). The flavonoids sideroxylin (20), 6-desmethyl-
sideroxylin (21) and 8-desmethyl-sideroxylin (22) were detected in the most active 
fraction from the first stage of fractionation (GS-4, which lowered the MIC of berberine 
from 150 μg/mL to 18 μg/mL), but did not display the expected large, negative selectivity 
ratios. This failure to identify the active flavonoids among other mixture components can 
be explained by the high level of complexity of these fractions and inability to resolve 
active and inactive compounds. These findings demonstrate an inherent limitation of 
metabolomic studies in which investigators attempt to identify active compounds from 
mixtures without prior fractionation.  
Notably, a number of ions were identified in this first stage fractionation with 
highly negative selectivity ratios (Figure 20A). It is unclear whether these ions (for which 
activity and structure are unknown) constitute a series of false positives, or whether they 
are truly active but hitherto unidentified constituents of H. canadensis. The data do 
suggest that at least one of the ions identified in Figure 20A is a false negative. The ion 
with the most negative SR (m/z 527.3156 [M+H]
+
) was most abundant (relatively, based 
upon MS signal) in fraction GS-8, which did not prove to be an active fraction (Figure 
18B). This highlights the potential for false positives when using this biochemometrics 
approach, and further supports the assertion that some fractionation is required to obtain 
useful selectivity ratio plots. In addition, ions that appear to be “active” in the stage 1 
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fractions are not present in later-stage selectivity ratio plots, which indicates that they are 
false positives and not true antimicrobials or antimicrobial synergists. 
GS-4 was chosen for further purification based upon its lowering of the MIC of 
berberine from 150 μg/mL to 18 μg/mL (Figure 18A). The resulting 16 fractions, 
excluding GS-4-1, lowered the MIC of berberine to values ranging between 2.34 μg/mL 
and 75 μg/mL, and the resulting selectivity ratio plot is shown in Figure 3B. As with 
stage 1 fractions, the known flavonoid synergists (20-22) and the antimicrobial alkaloid 
berberine (18) were detected in these fractions. In this less complex series of stage 2 
fractions, berberine (known to be active) displayed the expected negative selectivity ratio. 
However, the second stage of fractionation still failed to show activity for the known 
active flavonoids (20-22). Finally, as with the first stage fractionation, several ions of 
unknown identity displayed large negative selectivity ratios. The possible biological 
activity of these ions was not further pursued, but could be the subject of future 
investigations.  
Fraction GS-4-4 was the most bioactive from the second stage of fractionation, 
decreasing the MIC of berberine from 150 μg/mL to 2.3 μg/mL (Figure 18B). The nine 
subfractions of GS-4-4 were subjected to biochemometric analysis, resulting in the 
selectivity ratio plot shown in Figure 20C. Compounds 11 (m/z 359.1121 and 359.1122 
[M+H]
+
) and 27 (m/z 329.1017 [M+H]
+
 and 327.0879 [M-H]
-
) had the second and third 
lowest selectivity ratios, with the lowest SR representing m/z 373.1279 [M+H]
+ 
and its 
13
C isotope. This ion represented a compound not yet known to H. canadensis, and was 
targeted for isolation. Additionally, chilenine (12) and 4´,5´-dimethoxy-4-methyl-3´-
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oxo(1,2,5,6-tetrahydro-4H-1,3-dioxolo-[4´,5´:4,5]-benzo[1,2-e]-1,2-oxazocin)-2-spiro-1´-
phtalan (17) were identified as potential active components based on biochemometric 
analysis of the third stage fractions (Figure 20C). Chilenine has previously been reported 
as a constituent of H. canadensis, but its biological activity is unknown (114). The data 
presented here suggest that it might possess antimicrobial activity (alone or in 
combination with berberine), a possibility that could be investigated in a future study.  
Verification of activity for a compound predicted to be active based on 
biochemometrics 
Guided by the results of the biochemometric analysis (Figure 20C), 38 was 
isolated and identified as the new flavonoid 3,3´-dihydroxy- 5,7,4´-trimethoxy- 6,8-C-
dimethylflavone (Figures S30-S34). The isolated mass (0.84 mg) was insufficient for 
completing a full synergy assessment, so 38 was tested at a constant concentration (75 
μg/mL or 201.4 μM) in combination with concentrations of berberine ranging from 0 to 
100 μg/mL (297.5 μM) (Figure 21). The known efflux pump inhibitor piperine (123) was 
also included in this assay (at a constant concentration of 200 µM) as a positive control.  
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Figure 21. Dose Response Curve of Berberine Ranging From 0 to 298 μM In Combination With 
Piperine (Positive Control, Fixed Concentration of 263 μM) and 38 (Fixed Concentration of 200 μM). 
Error bars represent standard error (error bars are not visible for some datapoints because they are smaller 
than the point size). The expected shift to the left (increased potency) in the berberine dose-response curves 
in the presence of both piperine and 38 was observed. Notably, 38 did not have any antimicrobial effect 
when tested individually at 200 and 400 μM, which suggests that the increased potency of berberine in 
combination with this compound is due to synergy and not additivity. 
 
 
Both piperine and 38 influenced the activity of berberine (Figure 21). The MIC of 
berberine alone was 238 μM, but in combination with piperine and 38, the MIC was 
lowered to 119 μM and 179 μM, respectively. When tested in combination with 38, the 
IC50 of berberine was lowered from 132.2 ± 1.1 μM to 91.5 ± 1.1 μM. Piperine 
demonstrated a similar activity, resulting in a lowered berberine IC50 of 72.3 ± 1.0 μM. 
These data suggest that 38 does, indeed enhance the antimicrobial activity of berberine. 
Importantly, 38 alone at 402.8 μM and 201.4 μM demonstrated no antimicrobial activity 
(data not shown), suggesting that the increased efficacy of berberine in combination with 
38 is due to synergy, not additivity. Thus, 38, which has no antimicrobial activity alone, 
potentiates the antimicrobial efficacy of berberine. The potency of 38 in combination 
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with berberine is not high as that of the precursor fraction (GS-4-4-2, which lowered the 
MIC of berberine from 150 μg/mL to 4.68 μg/mL), which further supports that the 
activity of fraction GS-4-4-2 is due to the presence of multiple constituents, including 
compounds 20-22, 11, and 13. 
Did biochemometrics improve the synergy-directed fractionation process? 
Previous work using synergy-directed fractionation on H. canadensis (without 
biochemometrics) resulted in the identification of three flavonoids (20-22) that 
synergistically enhanced the antimicrobial activity of berberine (18) (9). The application 
of biochemometrics enabled the list of putative active compounds to be increased to be 
increased to nine compounds. Specifically, based on the biochemometrics data for the 
third stage of fractions (Figure 20C), the flavonoids 20, 21, 22, 11, 27, and 38 and the 
alkaloids 26, 12, and 17 were all predicted to act as additives or synergists to the 
antimicrobial activity of berberine. How accurate were these predictions? Compounds 
20-22, and 11 are known efflux pump inhibitors, as demonstrated in several previous 
studies (9, 114). Compound 27 has not previously been evaluated for biological activity 
against S. aureus, but has been shown to have antimicrobial activity against 
Streptococcus mutans and Fusobacterium nucleatum (87). Based upon its structural 
similarity to 20, which has one less hydroxy group at the C-3´ position, 27 is likely to be 
active as an efflux pump inhibitor. Compound 38 is a new compound, isolated as part of 
these studies, and demonstrated to increase synergistically the antimicrobial activity of 
berberine (Figure 21). It is likely that, like other flavonoids, the activity of 38 is due to 
bacterial efflux pump inhibition, although the efflux pump inhibitory activity of this 
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compound was not evaluated here. Alkaloid 26 was shown previously in the literature to 
not have antimicrobial activity against S. aureus when tested at 25.6 μg using a disk 
diffusion assay (119). Further studies would be needed to show if 26 is antimicrobial 
under other conditions and if it exhibits synergy in combination with berberine. Similarly, 
alkaloids 12 and 17 have no reported biological activity, and their activity as synergists or 
antimicrobials could be confirmed with further studies. As a side note, alkaloid 17 was 
found to be a product of β-hydrastine-N-oxide under reflux conditions and is likely 
present here as an isolation artifact (92, 114).  
A major challenge faced by any investigator conducting bioassay-guided 
fractionation is to decide which mixture components to target for isolation. The 
magnitude of this challenge is illustrated by the sheer number of ions detectable with 
mass spectrometric analysis of a botanical extract. In this study, a total of 595, 612 and 
149 features were detected (above the selected signal threshold) in the first, second, and 
third stage of H. canadensis fractionation, respectively. When addressing this challenge, 
the inclination of the investigator is to focus on the most detectable ions (which may or 
may not be the most abundant) in the most biologically active fraction. The application of 
biochemometrics to guide isolation helps reduce that inherent bias. Relevant to the study 
here, 38 was identified for isolation in this project because it has the lowest selectivity 
ratio in the third stage fractionation. Notably, this compound was not the ion detected 
with highest abundance in the most active fraction (GS-4-4-2, Figure 19D and 19H). 
Visual inspection of the data from that fraction would have led the observer to overlook 
38 and instead focus on 20, 21 and 22, which appear to be highly abundant and have 
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already been isolated and identified as synergists as part of a previous study. Ultimately, 
isolation and subsequent NMR structure elucidation will always be needed to confirm 
absolute configuration and solve structures of unknown compounds. Furthermore, given 
the correlative rather than causal nature of activity predictions based on biochemometric 
data analysis, isolation and biological activity evaluation are very necessary as a means of 
validation. As demonstrated here, the use of biochemometrics to integrate bioassay data 
with mass spectrometric metabolite profiles can help guide the isolation process towards 
constituents that may possess relevant biological activity. Importantly, however, as was 
the case in this study, the complexity of botanical extracts may necessitate several stages 
of fractionation to simplify the mixture before biochemometric analysis yields useful 
results. 
Experimental 
General experimental procedures 
Extracts were suspended in 1:1 MeOH-dioxane (LC/MS grade, Fisher Scientific, 
Hampton, NH, USA) at either 1 mg/mL or 0.1mg/mL and subjected to ultraperformance 
liquid chromatography tandem mass spectrometry (UPLC-MS/MS) analysis via a Waters 
Acquity UPLC with an Acquity UPLC column (BEH C18, 1.7 μm, 2.1 x 50 mm, Waters 
Corporation, Milford, MA, USA) and a Thermo Q-Exactive Plus orbitrap mass 
spectrometer with heated electrospray ionization (Thermo Fisher Scientific, Milford, MA, 
USA). Analysis was performed at a flow rate of 0.3 mL/min using the following binary 
solvent system with A consisting of water with 0.1% formic acid additive and solvent B 
consisting of acetonitrile with 0.1% formic acid additive (LC/MS grade, Fisher 
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Scientific). The gradient was as follows: 95:5 (A:B) from 0 to 1 min, increasing to 90:10 
(A:B) from 1 to 2 min, 80:20 (A:B) from 2 to 3 min, 60:40 (A:B) from 3 to 4 min, 70:30 
(A:B) from 4 to 5 min, 0:100 (A:B) from 5 to 6 min and held from 6 to 7 min, 95:5 (A:B) 
from 7 to 8 min and held from 8 to 9 min. The Thermo Q-Exactive Plus was operated in 
both positive and negative polarities using the following settings: spray voltage, 3.7 kV; 
capillary temperature, 350°C; sheath gas, 25; auxiliary gas, 5; S-lens RF level, 50. 
Known constituents of goldenseal were listed in an inclusion list for fragmentation via 
high-energy collision-induced dissociation (HCD) and used for tentative identification 
based upon matching retention time, accurate mass, and accurate mass fragments with 
isolated standards (compounds 20-22, 11, 13, 14, 26, 19, 23, 24, 12, 15-17, 25, and 10) 
(72). Compounds without standards (27-37) were identified tentatively by comparison of 
accurate mass and molecular formula with literature reports (11, 86, 88, 89, 114, 117). 
Data were visualized using Xcalibur (v. 2.3.26, Thermo Fisher Scientific). Phenomenex 
Gemini-NX C18 analytical (5 μm; 250 × 4.6 mm) and preparative (5 μm; 250 × 21.2 mm) 
and Phenomenex Luna PFP(2) 100A analytical (5 μm; 150 × 4.6 mm) and preparative (5 
μm; 250 × 21.2 mm, Phenomenex, Torrance, CA, USA) columns were used on a Varian 
Prostar HPLC system equipped with Prostar 210 pumps and a Prostar 335 photodiode 
array detector (PDA) (Agilent Technologies, Santa Clara, CA, USA), with data collected 
and analyzed using Galaxie Chromatography Workstation software (version 1.9.3.2, 
Agilent Technologies). Flash chromatography was performed on a Teledyne ISCO 
CombiFlash ® Rf 200 (Teledyne-Isco, Lincoln, NE, USA) using Silica Gold columns 
(330 g, 120 g, and 40 g columns) and monitored by UV and evaporative light-scattering 
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detectors. 1D and 2D NMR spectra were recorded using a JEOL ECA-500 NMR 
spectrometer operating at 400MHz for 
1
H and 100 MHz for 
13
C (JEOL, Peabody, MA, 
USA), or an Agilent 700 MHz NMR spectrometer (Agilent Technologies) equipped with 
a cryoprope, operating at 175 MHz for 
13
C. NMR data were visualized using 
MestReNova (v 11.0.4, Mestrelab Research, Santiago de Compostela, Spain). IC50 values 
were calculated using a four parameter logistic standard curve analysis function in 
SigmaPlot (v.13, Systat Software, San Jose, CA, USA). All chemicals used unless 
otherwise stated were ACS grade and obtained from Fisher Scientific. 
Plant material  
Hydrastis canadensis bulk leaf material was collected in June 2014 from William 
Burch in Hendersonville, North Carolina (NC, N 35°24.277’, W 082°20.993’, 702.4 m 
elevation). The plants were cultivated in their natural environment, a hardwood forest 
understory, and were a year old at the time of harvest. A voucher specimen for this H. 
canadensis plot has been deposited at the Herbarium of the University of North Carolina 
at Chapel Hill (NCU583414) and authenticated by Dr. Alan S. Weakly. Samples were 
dried at room temperature until crisp before extraction. 
Extraction and isolation 
Dried aerial plant portions were ground mechanically using a Wiley Mill Standard 
Model No. 3 (Arthur H. Thomas Co., Philadelphia, PA, USA) with a 2 mm mesh size, 
and percolated in MeOH overnight three times. The MeOH extract was concentrated in 
vacuo before liquid-liquid extraction. The extract was defatted by partitioning between 
hexane and 10% aqueous MeOH (1:1). The dried aqueous MeOH was partitioned further 
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between 4:5:1 EtOAc-MeOH-H2O, and the organic layer was washed with 1% saline 
solution to remove hydrosoluble tannins. The fractionation scheme is provided as 
Supporting Information. The first stage of normal-phase flash chromatography (330 g 
Gold silica gel column) was performed in two batches (58.49 g total) and conducted at a 
200 mL/min flow rate with a 42.7 min hexane/CHCl3/MeOH gradient. The most active 
fraction from the first stage separation (fraction 4, ~10 g) was subjected to a second stage 
of normal-phase flash chromatography (120 g Gold silica gel column and 40 g Gold silica 
gel column) and conducted at flow rates of 85 mL/min and 40 mL/min, respectively with 
57.6 min and 33.4 min hexane/EtOAc/MeOH gradients, respectively. The most active 
fraction from the second-stage separation (subfraction 4, ~290 mg) was purified using 
reversed-phase HPLC with a Phenomenex Gemini-NX column at a 21.4 mL/min flow 
rate in three batches. A CH3CN/H2O with 0.1% formic acid gradient was employed 
which held at 30:70 for five min, increased to 60:40 from five to ten min, increased to 
0:100 from 10 to 25 min, and held at 100:0 from 25 to 40 min. It was determined that the 
ion of interest via biochemometric analysis of the third stage of fractionation, m/z 
373.1279 [M+H]
+ 
had the greatest relative abundance in fraction GS-4-5 and was 
therefore used for isolation. GS-4-5 was subjected to reversed-phase HPLC with a 
preparative Luna PFP column at a 21.4 mL/min flow rate. A CH3CN/H2O with 0.1% 
formic acid gradient was employed that increased from 35:65 to 50:50 over 8 min, held at 
50:50 from 8 to 30 min, increased to 100:0 from 30 to 35 min, and then held at 100:0 
from 35 to 55 min. Fractions 41 through 43 were recombined and subjected to reversed-
phase HPLC with an analytical Luna PFP column at 1 mL/min. A MeOH/H2O with 0.1% 
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formic acid gradient was employed where the solvent composition increased from 72:28 
to 76:24 over 30 min, and increased to 100:0 from 30 to 40 min. Fractions were collected 
manually into vials based upon UV absorption and LC-MS traces. One last stage of 
purification was performed to achieve 95.4% purity via UV (254 nm) using a Gemini 
analytical column with a CH3CN/H2O with 0.1% formic acid solvent system at 1 mL/min 
where the gradient increased from 10:90 to 100:0 over 55 min, and held at 100:0 from 55 
to 60 min. Compound 38 had a final yield of 0.84 mg (0.0014% of 58.49 g EtOAc 
extract). 
3,3´-Dihydroxy-5,7,4´-trimethoxy-6,8-C-dimethyl-flavone (38): yellow solid; UV 
(MeOH) λmax (log ε) 254 (4.42) 363 (4.26) nm; 
1
H NMR (DMSO, 500 MHz, Figure S30) 
and 
13
C NMR (DMSO, 175 MHz, Figure S31), see Table 1; HRESIMS m/z 373.1279 
[M+H]
+
 (calcd for C20H21O7, 373.1287). Because there were no HMBC correlations for 
the hydroxy protons attached to C-3 and C-3´, OH-3´ was assigned based upon literature 
precedent that hydroxy group protons attached to aromatic rings have sharper peaks than 
those that are not (128). 
Antimicrobial assays 
Minimum inhibitory concentrations (MIC values) were evaluated per the terms 
outlined by the Clinical Laboratory Standards Institute (78) against wild type 
Staphylococcus aureus (SA1199) (102).(129)(129) A single colony inoculum was grown 
to log phase in Müeller Hinton broth and adjusted to a final assay concentration of 1.0 × 
10
5
 CFU/mL based on absorbance at 600 nm (OD600). The negative control consisted of 
2% glycerol and 2% DMSO in broth (vehicle), and the known antimicrobial compound 
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berberine (80) served as the positive control. Triplicate wells were prepared with all 
treatments and controls. Duplicate plates were made without bacteria for background 
absorbance subtraction. OD600 was read after 18 h at 37 °C using a Synergy H1 
microplate reader (Biotek, Winooski, VT, USA). The MIC was defined as the 
concentration at which no statistically significant difference was observed between the 
negative control and treated sample.  
Combination assays 
Extracts were tested in combination with berberine over a concentration range of 
2.3 to 150 µg/mL. Berberine alone served as a positive control, and demonstrated a MIC 
value between 75 and 150 µg/mL, consistent with the literature (9). The vehicle consisted 
of 2% glycerol and 2% DMSO in broth. A simplified version of the synergy assay was 
performed after each stage of fractionation to quickly assess those fractions possessing 
additive and/or synergistic behavior. This involved testing berberine at a range of 
concentrations (2.3 to 150 µg/mL) in combination with a constant concentration of each 
of the extract fractions (75 µg/mL) or purified compound 38 (200 µM). The known efflux 
pump inhibitor piperine (75 µg/mL or 240 µM) was used as the positive control for these 
experiments (123, 130). Fractions were classified as active if they enhanced the 
antimicrobial activity of berberine (lowered the MIC by 2-fold) and were advanced to the 
next stage of separation.  
Biochemometric analysis 
LC-MS data sets were collected in positive and negative polarities and were 
analyzed, aligned and filtered in independent batches using MZmine 2.17 software 
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(http://mzmine.sourceforge.net/) (131), as previously described by Kellogg et al (35). 
Briefly, raw data files were uploaded into MZmine for peak picking based upon mass 
spectral signals that were above the signal intensity of a mass spectrometric 
chromatogram of an injection of 1:1 MeOH:dioxane (solvent blank). Chromatograms 
were built based upon having a signal that lasted for longer than 0.01 min, minimum peak 
duration of 1.8 sec (0.03 min), m/z variation tolerance of 0.05 and a m/z intensity 
variation tolerance of 20%. Peak list filtering and retention time alignment were also 
performed, and the join align algorithm compiled the final peak list. The mass spectral 
data matrix was exported into Excel (Microsoft, Redmond, WA, USA) where ions in 
common between the samples and solvent blank was manually removed from the sample 
mass spectral profiles, positive and negative polarity data sets were combined and 
biological assay data was added in the form of MIC values of berberine in combination 
with certain fractions. Data matrices for each stage of fractionation were independently 
imported into Sirius version 10.0 (Pattern Recognition Systems AS, Bergen, Norway) 
(132). An internally cross-validated PLS model of 100 iterations with a significance 
threshold set to 0.05 was constructed and selectivity ratios were calculated using the 
Sirius software (32).  
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Table 5. NMR Spectroscopic Data (500 and 700 MHz, DMSO) for  
3,3´-Dihydroxy- 5,7,4´ trimethoxy- 6,8-C-dimethylflavone (38). 
 
position δC, type δH (J in Hz) HMBC
a 
2 143.35, C   
3 138.49, C   
4 171.79, C   
5 155.28, C   
6 121.39, C   
7 160.96, C   
8 115.60, C   
9 153.47, C   
10 112.83, C   
1´ 124.33, C   
2´ 114.60, CH 7.70, s 2, 3´, 4´, 6  ́
3´ 146.79, C   
4´ 149.47, C   
5´ 112.43, CH 7.09, d (14) 1´, 3´, 4´ 
6´ 119.65, CH 7.68, d (14) 2, 2´, 4´ 
OH-3  9.43, s  
OCH3-5 61.47,  3.75, s 5 
CH3-6 9.17,  2.18, s 6, 5, 7 
OCH3-7 60.83,  3.74, s 7 
CH3-8 9.43,  2.39, s 7, 8 ,9 
OH-3´  9.10, s  
OCH3-4´ 56.02,  3.81, s 4´ 
aHMBC correlations are from the proton(s) stated to the indicated carbon. 
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CHAPTER VI 
CONCLUDING REMARKS 
 
The studies described here demonstrate how the inclusion of liquid 
chromatography and mass spectrometry can improve the process of identifying bioactive 
constituents. Chapter II described the development of a mass spectrometry-based assay to 
identify inhibitor of the bacterial spreading factor hyaluronidase. This assay served as a 
direct, quantitative, accurate and precise alternative to existing methods that rely on 
turbidimetric or colorimetric measurements. Chapter III described the identification of 
two fungal metabolites, leotiomycene A and leotiomycene B, as the most potent 
inhibitors of Streptococcus agalactiae hyaluronidase to date. Leotiomycene B was also 
found to be the first ever reported inhibitor of hyaluronidase from Staphylococcus aureus. 
In addition, these compounds did not exhibit antimicrobial activity at the concentration in 
which they inhibit hyaluronidase, and thereby could serve as leads for the development of 
treatments to inhibit bacterial spreading.  
Chapter IV described the isolation of two new compounds and six previously 
known compounds that were new to Hydrastis canadensis. One of the new compounds, 
3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-C-dimethyl-flavone, was found to inhibit efflux 
pumps in Staphylococcus aureus, which supports the supposed effectiveness of H. 
canadensis as a treatment for bacterial skin infections. In addition, high mass accuracy 
fragmentation spectra were obtained for all isolated constituents and were uploaded into 
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the Global Natural Products Social molecular networking database to facilitate 
identification in other botanical extracts. These methods and data were used in Chapter 
V, which involved using H. canadensis as a case study for the application of multivariate 
statistics to identify synergists and additives in complex matrices. Untargeted 
metabolomics profiles of H. canadensis extracts and fractions were combined with 
bioassay data (termed biochemometrics) to produce selectivity ratio plots, which indicate 
the variation of correlation that components have with bioactivity. The approach 
identified a new compound, 3,3′-dihydroxy-5,7,4′-trimethoxy-6,8-C-dimethylflavone, 
along with other active flavonoids. When tested in combination with berberine against S. 
aureus, it was confirmed that this new compound was indeed a synergist. This study 
demonstrated the importance of fractionation when using metabolomics to identify 
bioactive constituents from complex matrices, as well as the power of selectivity ratio 
plots to aid in interpreting combined complex chemical and biological data sets.  
These studies clearly demonstrate the advantage of using mass spectrometry as a 
discovery tool in natural product research. The methods described here can be combined 
in order to find new inhibitors of bacterial spreading, or they can be applied to other 
botanicals or natural product mixtures with different biological effects. Based upon this 
work, continued improvement of these biological measurements, untargeted 
metabolomics experiments, and methods of complex data set combination is likely to 
result in even better ways to discover new treatments for disease.
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Table S1. Mass spectral data for isolated compounds in the positive ion mode. 
 
Table S2. Mass spectral data for isolated compounds in the negative ion mode. 
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Table S1. Mass spectral data for isolated compounds in the positive ion mode. 
 
Compound 
Molecular 
Formula 
Retention Time 
[M+H]
+ 
m/z
a
 
Fragments
b
 and 
Intensities 
10 C11H12O6 4.61 241.0702 209.0440(100) 
     
11 C19H18O7 5.95 359.1118 
359.1116(84) 
344.0882(100) 
329.0648(47) 
301.0700(26) 
273.0750(28) 
195.0648(42) 
     
12 C20H17NO7 5.06 384.1073 
384.0964(20) 
366.0964(48) 
338.1014(54) 
322.0703(25) 
294.0754(30) 
149.0595(100) 
199.0490(60) 
91.0541(63) 
     
13 C17H16O5 5.87 301.1069 
301.1063(10) 
181.0492(100) 
147.0438(60) 
119.0489(20) 
     
14 C18H18O5 5.92 315.1217 
315.1206(8) 
299.0858(7) 
195.0648(100) 
147.0437(50) 
119.0541(16) 
     
15 C10H9NO3 4.31 192.0651 
192.0650(100) 
174.0546(17) 
149.0594(90) 
119.0489(27) 
91.05423 (18) 
     
16 C11H11NO3 4.70 206.0809 
206.0806(92) 
149.0594(100) 
119.0489(32) 
91.05408(26) 
     
17 C21H21NO7 5.84 400.1388 
335.0902(27) 
320.0657(38) 
311.0904(100) 
296.0670(60) 
253.0851(36) 
193.0491(60) 
190.0585(93) 
aThe reported values for m/z of the [M+H]+ ion are all within 5 ppm of the calculated m/z for the molecular formula indicated.  
b m/z values of the fragment ions are measured with a mass error of ≤ 10   
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Table S1 (cont.). Mass spectral data for isolated compounds in the positive ion mode (continued). 
 
Compound 
Molecular 
Formula 
Retention Time 
[M+H]
+ 
m/z
a
 
Fragments
b
 and 
Intensities 
18 C20H18NO4 4.74 336.1225 
336.1219(36) 
321.0982(50) 
320.0908(100) 
307.0814(12) 
306.0752(29) 
304.0959(22) 
292.0959(82) 
     
19 C20H21NO4 4.52 340.1540 
340.1535(6) 
176.0702(100) 
149.0594(10) 
     
20 C18H16O5 6.15 313.1066 
313.1061(80) 
298.0826(100) 
297.0749(38) 
     
21 C17H14O5 
5.82 
299.0911 
299.0906(100) 
284.0671(54) 
256.0722(15) 
     
22 C17H14O5 
5.93 
299.09140 
299.0906(100) 
284.0670(26) 
283.0594(20) 
     
23 C21H21NO6 4.26 384.14389 
323.0905(67) 
293.0798(76) 
265.0852(35) 
190.0859(100) 
     
24 C20H19NO5 5.62 354.13287 
354.1327(26) 
339.1093(11) 
176.0703(100) 
164.0464(42) 
     
25 C19H17NO5 5.38 340.11725 
340.1172(17) 
325.0936(18) 
176.0703(100) 
150.0309(12) 
     
26 C20H17NO5 5.68 352.11749 
352.1170(6) 
337.0935(39) 
322.0702(100) 
308.0910(10) 
294.0753(23) 
a
The reported values for m/z of the [M+H]+ ion are all within 5 ppm of the calculated m/z for the molecular formula indicated.  
b
 m/z values of the fragment ions are measured with a mass error of ≤ 10  
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Table S2. Mass spectral data for isolated compounds in the negative ion mode. 
 
Compound 
Molecular 
Formula 
Retention Time 
[M-H]
-
  
m/z
a
 
Fragments
b
 and 
Intensities 
10 
C11H12O6 4.76 239.0562 
163.0401(30) 
148.0167(100) 
133.0296(20) 
123.0453(20) 
108.0218(28) 
     
13 C17H16O5 5.97 299.0923 
179.035(30) 
164.0116(18) 
119.0502(100) 
93.0346(11) 
79.019(9) 
     
20 C18H16O5 6.09 311.0923 
311.0926(4) 
296.0689(100) 
295.0612(18) 
     
21 C17H14O5 5.92 297.0764 
297.0767(12) 
283.0567(8) 
282.0533(100) 
281.0455(16) 
     
22 C17H14O5 6.03 297.0766 
297.0767(12) 
283.0567(8) 
282.0533(100) 
281.0456(15) 
a 
The reported values for m/z of the [M+H]+ ion are all within 5 ppm of the calculated m/z for the molecular formula indicated.  
b
 m/z values of the fragment ions are measured with a mass error of ≤ 10  
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APPENDIX B 
SUPPLEMENTARY FIGURES 
 
 
Figure S1. Time dependent reactions that display the relative amount of 
disaccharides produced as a function of time with a logarithmic fit of y = 4 × 
10
6
ln(x) - 6 × 10
6
 (R
2 
= 0.8946) 
 
Figure S2. Fractionation scheme: H. canadensis leaves were percolated in MeOH, 
subjected to liquid/liquid partitioning. The compounds were isolated using three 
subsequent stages of chromatography, two rounds of flash chromatography over 
silica gel and a preparatory scale HPLC 
 
Figure S3. 
1
H NMR spectrum (400 MHz, CDCl3) of 3,4-dimethoxy-2-
(methoxycarbonyl)benzoic acid (10) 
 
Figure S4. 
13
C NMR spectrum (100 MHz, CDCl3) of 3,4-dimethoxy-2-
(methoxycarbonyl)benzoic acid (10) 
 
Figure S5. HSQC spectrum of 3,4-dimethoxy-2-(methoxycarbonyl)benzoic acid (10) 
 
Figure S6. HMBC spectrum of 3,4-dimethoxy-2-(methoxycarbonyl)benzoic acid (10) 
 
Figure S7. COSY spectrum of 3,4-dimethoxy-2-(methoxycarbonyl)benzoic acid (10) 
 
Figure S8. 
1
H NMR spectrum (400 MHz, CDCl3) of 3,5,3´-trihydroxy-7,4´-
dimethoxy-6,8-C-dimethyl-flavone (11) 
 
Figure S9. 
13
C NMR spectrum (100 MHz, CDCl3) of 3,5,3´-trihydroxy-7,4´-
dimethoxy-6,8-C-dimethyl-flavone (11) 
 
Figure S10. HSQC spectrum of 3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-C-dimethyl-
flavone (11) 
 
Figure S11. HMBC spectrum of 3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-C-dimethyl-
flavone (11) 
 
Figure S12. COSY spectrum of 3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-C-dimethyl-
flavone (11) 
 
Figure S13. 
1
H NMR spectrum (400 MHz, CDCl3) of chilenine (12) 
 
Figure S14. 
13
C NMR spectrum (100 MHz, CDCl3) of chilenine (12) 
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Figure S15. 
1
H NMR spectrum (400 MHz, CDCl3) of 5,4´-dihydroxy-6-C-methyl-7-
methoxy-flavanone (13) 
 
Figure S16. 
13
C NMR spectrum (100 MHz, CDCl3) of 5,4´-dihydroxy-6-C-methyl-7-
methoxy-flavanone (13) 
 
Figure S17. 
1
H NMR spectrum (400 MHz, CDCl3) of 5,4´-dihydroxy-6,8-di-C-
methyl-7-methoxy-flavanone (14) 
 
Figure S18. 
13
C NMR spectrum (100 MHz, CDCl3) of 5,4´-dihydroxy-6,8-di-C-
methyl-7-methoxy-flavanone (14) 
 
Figure S19. 
1
H NMR spectrum (400 MHz, CDCl3) of noroxyhydrastinine (15) 
 
Figure S20. 
13
C NMR spectrum (100 MHz, CDCl3) of noroxyhydrastinine (15) 
  
Figure S21. HSQC spectrum of noroxyhydrastinine (15) 
 
Figure S22. HMBC spectrum of noroxyhydrastinine (15) 
 
Figure S23. 
1
H NMR spectrum (400 MHz, CDCl3) of oxyhydrastinine (16) 
 
Figure S24. 
13
C NMR spectrum (400 MHz, CDCl3) of oxyhydrastinine (16) 
 
Figure S25. 
1
H NMR spectrum (400 MHz, CDCl3) of 4´,5´-dimethoxy-4-methyl-3´-
oxo(1,2,5,6-tetrahydro-4H-1,3-dioxolo-[4´,5´:4,5]-benzo[1,2-e]-1,2-oxazocin)-2-spiro-
1´-phtalan (17) 
 
Figure S26. 
13
C NMR spectrum (100 MHz, CDCl3) of 4´,5´-dimethoxy-4-methyl-3´-
oxo(1,2,5,6-tetrahydro-4H-1,3-dioxolo-[4´,5´:4,5]-benzo[1,2-e]-1,2-oxazocin)-2-spiro-
1´-phtalan (17) 
 
Figure S27. Fragmentation spectra of berberine 
 
Figure S28. Fractionation scheme 
 
Figure S29. MIC curves for the 4 stages of fractionation 
 
Figure S30. 
1
H NMR spectra of 3,3´-dihydroxy- 5,7,4´ trimethoxy-6,8-C-dimethyl-
flavone (38) 
 
Figure S31. 
13
C NMR spectra of 38 
 
Figure S32. HSQC NMR spectra of 38 
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Figure S33. HMBC NMR spectra of 38 
 
Figure S34. COSY NMR spectra of 38 
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Figure S1. Time dependent reactions that display the relative amount of disaccharides produced as a 
function of time with a logarithmic fit of y = 4 × 10
6
ln(x) - 6 × 10
6
 (R
2 
= 0.8946). The reaction time of 15 
min was selected for this assay on the basis of these data.  
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Figure S2. Fractionation scheme: H. canadensis leaves were percolated in MeOH, subjected to 
liquid/liquid partitioning. The compounds were isolated using three subsequent stages of 
chromatography, two rounds of flash chromatography over silica gel and a preparatory scale HPLC.  
Hydrastis canadensis  
(dried batches ) 
MeOH extract Residue 
Aq. MeOH extract Hexane extract 
Aq. extract EtOAc-MeOH extract 
Organic extract 
Tannin-free 
Aq. extract 
FI FII FIII FIV FV FVI FVII FVIII 
FII-1 FII-2 FII-3 FII-4 FII-5 FIII-1 FIII-2 FIII-3 FIV-1 FIV-2 FIV-3 FIV-4 FIV-5 FIV-6 
1st Stage Separation 
NP-FC Hex-CHCl3-MeOH 
 
2nd Stage Separation 
NP-FC Hex-EtOAc-MeOH 
 
5,4’-dihydroxy-6-C-methyl-7-
methoxy-flavanone	 
5,4’-dihydroxy-6,8-di-C-methyl-7-
methoxy-flavanone	 
3,5,3´-trihydroxy-7,4´-
dimethoxy-6,8-C-dimethyl-flavone	 
4´,5´-dimethoxy-4-methyl-3´-oxo-
(1,2,5,6-tetrahydro-4H-1,3-dioxolo-
[4´,5´:4,5]-benzo[1,2-e]-1,2-
oxazocin)-2-spiro-1´-phtalan	 
noroxyhydras nine	 
oxyhydras nine	 
chilenine	 
5,4’-dihydroxy-6-C-methyl-7-
methoxy-flavanone	 
chilenine	 3,4-dimethoxy-2-
(methoxycarbonyl)	
benzoic	acid	 
3rd Stage Separation 
RP-Prep MeOH-H2O  
(0.1% formic acid) 
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Figure S3. 
1
H NMR spectrum (400 MHz, CDCl3) of 3,4-dimethoxy-2-(methoxycarbonyl)benzoic acid 
(10). 
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Figure S4. 
13
C NMR spectrum (100 MHz, CDCl3) of 3,4-dimethoxy-2-(methoxycarbonyl)benzoic acid 
(10). 
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Figure S5. HSQC spectrum of 3,4-dimethoxy-2-(methoxycarbonyl)benzoic acid (10). 
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Figure S6. HMBC spectrum of 3,4-dimethoxy-2-(methoxycarbonyl)benzoic acid (10). 
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Figure S7. COSY spectrum of 3,4-dimethoxy-2-(methoxycarbonyl)benzoic acid (10). 
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Figure S8. 
1
H NMR spectrum (400 MHz, CDCl3) of 3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-C-dimethyl-
flavone (11). 
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Figure S9. 
13
C NMR spectrum (100 MHz, CDCl3) of 3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-C-
dimethyl-flavone (11). 
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Figure S10. HSQC spectrum of 3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-C-dimethyl-flavone (11). 
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Figure S11. HMBC spectrum of 3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-C-dimethyl-flavone (11). 
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Figure S12. COSY spectrum of 3,5,3´-trihydroxy-7,4´-dimethoxy-6,8-C-dimethyl-flavone (11). 
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Figure S13. 
1
H NMR spectrum (400 MHz, CDCl3) of chilenine (12). 
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Figure S14. 
13
C NMR spectrum (100 MHz, CDCl3) of chilenine (12). 
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Figure S15. 
1
H NMR spectrum (400 MHz, CDCl3) of (2R)-5,4´-dihydroxy-6-C-methyl-7-methoxy-
flavanone (13). 
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Figure S16. 
13
C NMR spectrum (100 MHz, CDCl3) of (2R)-5,4´-dihydroxy-6-C-methyl-7-methoxy-
flavanone (13). 
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Figure S17. 
1
H NMR spectrum (400 MHz, CDCl3) of 5,4´-dihydroxy-6,8-di-C-methyl-7-methoxy-
flavanone (14). 
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Figure S18. 
13
C NMR spectrum (100 MHz, CDCl3) of 5,4´-dihydroxy-6,8-di-C-methyl-7-methoxy-
flavanone (14). 
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Figure S19. 
1
H NMR spectrum (400 MHz, CDCl3) of noroxyhydrastinine (15). 
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Figure S20. 
13
C NMR spectrum (100 MHz, CDCl3) of noroxyhydrastinine (15). 
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Figure S21. HSQC spectrum of noroxyhydrastinine (15). 
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Figure S22. HMBC spectrum of noroxyhydrastinine (15). 
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Figure S23. 
1
H NMR spectrum (400 MHz, CDCl3) of oxyhydrastinine (16). 
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Figure S24. 
13
C NMR spectrum (400 MHz, CDCl3) of oxyhydrastinine (16). 
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Figure S25. 
1
H NMR spectrum (400 MHz, CDCl3) of 4´,5´-dimethoxy-4-methyl-3´-oxo(1,2,5,6-
tetrahydro-4H-1,3-dioxolo-[4´,5´:4,5]-benzo[1,2-e]-1,2-oxazocin)-2-spiro-1´-phtalan (17). 
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Figure S26. 
13
C NMR spectrum (100 MHz, CDCl3) of 4´,5´-dimethoxy-4-methyl-3´-oxo(1,2,5,6-
tetrahydro-4H-1,3-dioxolo-[4´,5´:4,5]-benzo[1,2-e]-1,2-oxazocin)-2-spiro-1´-phtalan (17). 
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Figure S27. Accurate mass fragmentation spectrum of berberine (18) in the positive polarity. 
Fragments and molecular formulas were predicted using ACD MS fragmenter (Advanced Chemistry 
Development, Inc. Toronto, Canada) and compared to experimental data. Bold ions had a mass error within 
10 ppm of the associated molecular formula. 
 
129 
 
 
Figure S28. Fractionation scheme. 
 
 
130 
 
 
 
Figure S29. Minimum inhibitory concentration (MIC) curves for berberine in combination with a 
constant concentration of fraction (75 μg/mL). Each point represents the average OD600 of three wells 
with identical treatments, and error bars represent standard error of those measurements. 
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Figure S30. 
1
H NMR spectra of 3,3´-dihydroxy- 5,7,4´ trimethoxy- 6,8-C-dimethyl-flavone (38). 
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Figure S31. 
13
C NMR spectra of 38. 
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Figure S32. HSQC NMR spectra of 38. 
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Figure S33. HMBC NMR spectra of 38. 
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Figure S34. COSY NMR spectra of 38. 
